Value Health Sols., Inc. v. Pharm. Rsch. Assocs., 2021 Ncbc 24a

Value Health Sols., Inc. v. Pharm. Rsch. Assocs., 2021 NCBC 24A.

STATE OF NORTH CAROLINA IN THE GENERAL COURT OF JUSTICE

SUPERIOR COURT DIVISION

COUNTY OF WAKE 18-CV-12318

VALUE HEALTH SOLUTIONS

INC. and NAGARAJAN

PARTHASARATHY,

Plaintiffs,

v. ORDER AND OPINION ON MOTIONS

FOR SUMMARY JUDGMENT

PHARMACEUTICAL

RESEARCH ASSOCIATES, INC.

and PRA HEALTH SCIENCES,

INC.,

Defendants.

THIS MATTER comes before the Court on Defendants Pharmaceutical

Research Associates, Inc. (“PRA, Inc.”) and PRA Health Sciences, Inc.’s (“PRAHS”;

collectively, Defendants will be referred to as “PRA,” in the singular, except as

otherwise required) Motion for Summary Judgment (“PRA’s Motion,” ECF No. 110)

and Plaintiffs Value Health Solutions Inc. (“VHS”) and Nagarajan Parthasarathy’s

(“Parthasarathy”) Motion for Summary Judgment. (“Plaintiffs’ Motion,” ECF No.

115; collectively, PRA’s Motion and Plaintiffs’ Motion are the “Motions”).

THE COURT, having considered the Motions, the evidence filed by the parties,

the briefs submitted in support of and in opposition to the Motions, the arguments of

counsel at the hearing on the Motions, the applicable law, and other appropriate

matters of record, CONCLUDES that PRA’s Motion should be GRANTED, and

Plaintiffs’ Motion should be GRANTED, in part, and DENIED, in part.

Mainsail Lawyers, by David Glen Guidry and Joseph Kellam Warren,

for Plaintiffs Value Health Solutions Inc. and Nagarajan Parthasarathy.

Barnes & Thornhill, LLP, by John M. Moye, and Allen R. Baum, and

Kilpatrick Townsend & Stockton LLP, by Joe P. Reynolds, for

Defendants Pharmaceutical Research Associates, Inc. and PRA Health

Sciences, Inc.

McGuire, Judge.

I. FACTUAL AND PROCEDURAL BACKGROUND

1. This matter arises from bitter disputes between the parties surrounding

PRA’s acquisition of VHS, its proprietary software, and Parthasarathy’s employment.

The action was filed in October 2018, and the parties engaged in lengthy and

extensive discovery involving the taking of at least seventeen depositions and the

exchange of many thousands of documents. During the litigation the parties sought

numerous orders sealing documents filed with the Court. Unfortunately, in

presenting the Motions to the Court, the parties have filed hundreds of individual

exhibits consisting of thousands of pages. The exhibits were filed in six 1 separate

filings, some of which consisted of dozens of individual exhibits contained in a single,

multi-hundred page and unindexed .pdf file. As a result, the Court’s review of the

record has been exceedingly difficult and time consuming. To expedite ruling on the

Motions and to simplify reference to the evidence in the record, the Court has chosen

to limit citation to the record to the extent possible and, in many cases, cites to those

portions of the parties’ briefs containing reference to the relevant evidence rather

than the exhibits containing the evidence.

1 The six filings include only the public, redacted filings, and not the companion sealed filings.

A. The Parties

2. PRA is a large, publicly traded, contract research organization (“CRO”)

that provides a range of clinical trial services to large pharmaceutical companies and

biotechnology companies around the globe. PRA is headquartered in Raleigh, North

Carolina, employs more than 17,500 employees worldwide, and has participated in

approximately 4,000 clinical trials across the globe, resulting in the regulatory

approval of over 95 drugs. At all times relevant to this matter, Colin Shannon

(“Shannon”) was PRA’s Chief Executive Officer, and Mike Irene (“Irene”) was PRA’s

Executive Director of IT. (PRA’s Br. Supp. of Mot. For SJ, ECF Nos. 111 [SEALED]

and 113 [Public], at p. 1.)

3. PRA uses clinical trial management software (“CTMS”) to assist its

customers with clinical trials. The CTMS used by PRA is critical to the services PRA

provides to its customers. In 2014, PRA was using a CTMS system created by Seibel.

(Id.)

4. Parthasarathy founded VHS. In 2013, VHS developed a set of clinical

trial software applications called ClinTrial Max (“CTMax”), Cloud Max, and Info Max

(collectively, the “Solutions”). CTMax was a Salesforce®-based CTMS. (Id. at p. 2;

Plfs.’ Br. Supp. Mot. For SJ, ECF Nos. 116 [SEALED] and 117.1 [Public], at pp. 2–3.)

B. PRA’s Acquisition of the Solutions

5. In 2014 PRA’s IT department was pursuing a transition to a Salesforce®

environment. In April 2014, PRA approached Parthasarathy about acquiring

CTMax, and Plaintiffs and PRA subsequently engaged in a year-long period of

negotiation and due diligence aimed at PRA’s acquisition of the Solutions. In addition

to negotiating over PRA’s purchase of the Solutions in order to integrate the software

into PRA’s clinical trial management environment, Shannon and Parthasarathy

discussed the potential for selling a stand-alone CTMS software to PRA’s customers.

(ECF Nos. 111/113, at pp. 2–3.)

6. Between April and October 2014, as part of the due diligence process,

VHS provided PRA full access to the software code for CTMax, and PRA performed

testing and analysis to understand its functionality. This included a gap analysis

which allowed PRA to learn CTMax’s capabilities and identify the functions that PRA

wanted to further develop after acquiring the software. In doing so, it became clear

that CTMax had several functional gaps compared to other CTMS applications in the

industry, including the Siebel CTMS then in use by PRA, and PRA advised

Parthasarathy of these gaps. (Id. at p. 3.) In July 2014, Irene prepared a list of key

product enhancements that PRA would need to “close the gap between CTMax and

[PRA’s] current CTMS.” (Id.)

i. The Letter of Intent

7. On October 15, 2014, PRA’s Health Executive Vice President and Chief

Financial Officer, Linda Baddour, sent Parthasarathy a document titled “Non-

Binding Letter of Intent” (“LOI”). (ECF No. 5, at Ex. A.) The LOI outlined PRA’s

proposal for the acquisition of the Solutions including, inter alia, as follows:

a. PRA would make a one-time, up-front payment to

Plaintiffs of between $1 million and $3 million;

b. PRA would make incentive payments of $333,000 each

conditioned upon successful completion of three

separate “Integration Milestones,” described as (i)

“Integrated Salesforce Environments,” (ii) “Key Product

Enhancements,” and (iii) “CTMS Studies Migrated to

ClinTrial Max” within 18 months following the closing

of the transaction; and

c. PRA would make future incentive payments to

Plaintiffs for achieving “Performance Milestones”

regarding external sales of “licenses for VHS offerings”

as follows:

i. a payment of $2.5 million for reaching $25

million in annual sales within two years of

closing;

ii. a payment of $5 million for reaching $50 million

in annual sales within three years of closing;

iii. a payment of $7.5 million for reaching $75

million in annual sales within four years of the

closing; and

iv. payment of a one percent (1%) annual royalty on

sales for an additional four years after the $75

million sales amount is reached.

(Id. at pp. 4–5.)

8. The LOI also stated as follows:

It is understood that this letter merely constitutes a

statement of the intentions of the parties with respect to a

potential Transaction, and does not contain all matters

upon which agreement must be reached in order for a

definitive agreement to be finalized or for the Transaction

to be consummated. Except for sections 3 through 8 of this

LOI, which shall be legally binding in accordance with

their respective terms, neither this LOI nor the acceptance

thereof is intended to, nor shall it, create a binding legal

obligation, or any obligation by any of the parties hereto to

enter into any Transaction, negotiate or take any other

action in contemplation thereof, or executive any definitive

agreements. The parties further acknowledge and agree

that, except as otherwise provided in the immediately

preceding sentence, none of this LOI, any proposal made to

the Company, nor the current on-going discussions

between the parties are intended to (and shall not) create

a legally binding obligation or commitment on the part of

any party with respect to the negotiation or completion of

the Transaction.

...

(Id. at p. 2.) The copy of the LOI provided in the record is not signed by VHS or

Parthasarathy, but Plaintiffs do not dispute that they entered into the LOI.

ii. The Asset Purchase Agreement

9. Effective May 21, 2015, PRA, VHS, and Parthasarathy entered into an

Asset Purchase Agreement (“APA”) for the purchase of the Solutions. (ECF No. 112.1,

at pp. 348–416.) The APA is governed by Delaware law.

10. Under the APA, Plaintiffs agreed to sell the Solutions to PRA for a

payment of PRA stock and cash of approximately $2.5 million at closing, and potential

“Contingent Payments” tied to achievement of certain milestones. (Id. at pp. 351–

52.) The first group of contingent payments were three separate payments dependent

on, respectively: the integration of CTMax into PRA’s clinical trial management

environment; the completion of the product enhancements to CTMax identified by

the gap analysis; and completion of the migration of PRA clinical trial studies into

CTMax (“Development Milestones”). (Id. at pp. 351, 387–90.) More specifically,

Article 2.6 of the APA provides:

Milestones. As additional consideration for the transactions

contemplated hereby, and subject to the terms of this

Section 2.6, Purchaser shall make (or PRAHS shall make on

Purchaser’s behalf) the following payments (each, a

“Contingent Payment”):

(i) upon completion of the integration of the parties’

Salesforce™ environments set forth on Schedule

2.6(a)(i), PRAHS shall issue to Seller (or as

otherwise directed by Seller’s Representative),

within thirty (30) days after such completion, that

number of shares of PRA Common Stock equal in

value to Three Hundred Thirty-Three Thousand

U.S. Dollars ($333,000.00), based on the Fair

Market Value as of the date of issuance of such

shares; provided, however, that completion occurs

within the first consecutive eighteen (18) months

from the Effective Time 2 (the “Integration Period”);

(ii) upon completion of the key product enhancements

set forth on Schedule 2.6(a)(ii). PRAHS shall issue to

Seller (or as otherwise directed by Seller’s

Representative), within thirty (30) days after such

completion, that number of shares of PRA Common

Stock equal in value to Three Hundred Thirty-Three

Thousand U.S. Dollars ($333,000.00), based on the

Fair Market Value as of the date of issuance of such

shares; provided, however, that completion occurs

within the Integration Period;

(iii) upon completion of the migration of the clinical trial

management systems studies of Purchaser and its

Affiliates into ClinTrial Max as set forth on Schedule

2.6(a)(iii), PRAHS shall issue to Seller (or as

otherwise directed by Seller’s Representative),

within thirty (30) days after such completion, that

number of shares of PRA Common Stock equal in

value to Three Hundred Thirty-Three Thousand

U.S. Dollars ($333,000.00), based on the Fair

Market Value as of the date of issuance of such

shares; provided, however, that completion occurs

within the Integration Period[.]

(Id. at pp. 351–52; emphasis in original.) Schedules 2.6(a)(i)–(iii) to the APA provide

further detail as to the requirements for achieving each of the Development

2 The “Effective Time” is defined in the APA as 11:59 p.m. (EST) on the Closing Date. Id. at

p. 353.)

Milestones and state that each Development Milestone “shall be deemed completed .

. . as reasonably determined by [PRA].” (Id. at pp. 387–90.)

11. The second group of contingent payments provided for in the APA were

conditioned on PRA achieving certain levels of “External Sales” of licenses to the

Solutions within four years following the Closing (“Sales Milestones;” collectively the

Sales Milestones and the Development Milestones are the “Milestones”). (Id. at pp.

352, 374.) Article 2.6 of the APA provides:

(iv) upon the achievement of aggregate External Sales

equal to Twenty Five Million U.S. Dollars

($25,000,000), Purchaser shall make, within thirty

(30) days following the date on which PRAHS files

its next quarterly report with the United States

Securities and Exchange Commission (the “SEC”)

after such achievement, a cash payment of Two

Million Five Hundred Thousand U.S. Dollars

($2,500,000.00) to Seller (or as otherwise directed by

Seller’s Representative) (the “First Milestone

Payment”); provided, however, that such

achievement occurs prior to the second (2nd)

anniversary of the Closing Date (the “First

Milestone Period”);

(v) upon the achievement of aggregate External Sales

equal to Fifty Million U.S. Dollars ($50,000,000.00),

Purchaser shall make, within thirty (30) days

following the date on which PRAHS files its next

quarterly report with the SEC after achievement, a

cash payment of Five Million U.S. Dollars

($5,000,000.00) to Seller (or as otherwise directed by

Seller’s Representative) (the “Second Milestone

Payment”); provided, however, that such

achievement occurs prior to the third (3rd)

anniversary of the Closing Date (the “Second

Milestone Period”);

(vi) upon the achievement of aggregate External Sales

equal to Seventy Five Million U.S. Dollars

($75,000,000.00), Purchaser shall make, within

thirty (30) days following the date on which PRAHS

files its next quarterly report with the SEC after

achievement, a cash payment of Seven Million Five

Hundred Thousand U.S. Dollars ($7,500,000.00) to

Seller (or as otherwise directed by Seller’s

Representative) (the “Third Milestone Payment”);

provided, however, that such achievement occurs

prior to the fourth (4th) anniversary of the Closing

Date (the “Third Milestone Period”); and

(vii) for four (4) consecutive calendar years following the

achievement of aggregate External Sales equal to

Seventy-Five Million U.S. Dollars ($75,000,000.00)

(the “Major Milestone”, and the date on which the

Major Milestone is achieved, the “Major Milestone

Date”), Purchaser shall make, within thirty (30)

days following the date on which PRAHS files its

next quarterly report with the SEC after each of the

four (4) anniversaries of the Major Milestone Date,

a per annum royalty payment to Seller (or as

otherwise directed by Seller’s Representative) equal

to one percent (1%) of the aggregate amount of

External Sales made during the applicable calendar

year (such payments, the “Royalty Payments”). For

the avoidance of doubt, any such Royalty Payments

shall be made regardless of whether the First

Milestone Payment, the Second Milestone Payment

and/or the Third Milestone Payment have

previously been made).

(Id. at p. 352; emphasis in original.) The APA provides that “External Sales” “means

the sale of one or more licenses to the Solutions by [PRA] or one of its Affiliates to a

third party which is not (i) an Affiliate of [PRA] or (ii) using such license(s) in

connection with providing services to [PRA] and/or any of its Affiliates.” (Id. at p.

374.)

12. The APA further states that contingent payments provided for in the

individual Development and Sales Milestones are “independent” obligations of PRA:

Independence of Contingent Payments. [PRA]’s obligation

to pay the Contingent Payments to [Plaintiffs] (or as

otherwise directed by [Plaintiffs’] Representative) in

accordance with Section 2.6(a) is an independent obligation

of [PRA] and is not otherwise conditioned or contingent

upon the satisfaction of any conditions precedent to any

preceding or subsequent Contingent Payment and the

obligation to pay a Contingent Payment to [Plaintiffs] (or

as otherwise directed by [Plaintiffs’] Representative) shall

not obligate [PRA] to pay any preceding or subsequent

Contingent Payment. For the avoidance of doubt and by

way of example, if the conditions precedent to the payment

of the First Milestone Payment for the First Milestone

Period are not satisfied, but the conditions precedent to the

payment of the Second Milestone Payment for the Second

Milestone Period are satisfied, then [PRA] would be

obligated to pay such Second Milestone Payment for the

Second Milestone Period for which the corresponding

conditions precedent have been satisfied, and not the First

Milestone Payment for the First Milestone Period.

(Id. at pp. 352–53.)

13. Finally, the APA contained a merger clause that provides as follows:

Entire Agreement. This Agreement, including the

Schedules and Exhibits hereto, constitutes the entire

agreement of the parties with respect to the subject matter

hereof and supersedes all prior discussions, negotiations,

and understandings.

(Id. at p. 371.)

14. Plaintiffs have acknowledged that the contingent payments provided for

in Article 2.6 of the APA were “never guaranteed” and were dependent on PRA

achieving the Milestones. (Pls.’ Mem. Supp. of Pls.’ Mot. Dismiss Counterclaims, ECF

No. 42, at p. 13.) 3

3 In their Mem. Supp. of Pls.’ Mot. Dismiss Counterclaims, Plaintiffs state:

C. Parthasarathy’s Employment Agreement with PRA

15. In connection with the APA, PRA hired Parthasarathy as an employee. 4

On June 8, 2015, PRA executed an Employment Agreement with Parthasarathy,

hiring him as a Vice President of Technology for PRA, Inc. (“Employment

Agreement,” ECF No. 8.3.) The Employment Agreement states that Parthasarathy

will have the “status and responsibilities as determined from time to time by” PRA’s

“CEO or the CEO’s designee” and that the CEO or designee “will determine”

Parthasarathy’s “specific duties . . . and the means and manner by which [he] will

perform those duties.” (Id. at p. 1) The Employment Agreement does not expressly

assign Parthasarathy any specific job duties associated with achievement of the

Milestones.

16. The Employment Agreement also provides that Parthasarathy will use

his “best efforts . . . and [ ] devote [his] full time, skill, attention, and energies to

[PRA’s] business,” and that he will not engage in “business activity which is

The Milestones are, however, by their very nature, contingent

and achievement of the Milestones was never guaranteed. See

ECF No. 37, Ex. A at § 2.6(a)(i)-(vii). Indeed, that is why the

Milestones provide that Plaintiffs would be entitled to

additional, contingent consideration upon the [ ] Solutions’

achievement of various requirements. Id. Nothing in the APA

states that achievement of the Milestones was guaranteed.

Indeed, a cursory reading of the APA makes clear that the

Milestones in Section 2.6 were not guaranteed because the APA

states Plaintiffs would receive additional payments “provided,

however, that the completion occurs within the Integration

Period.

(Id.)

4 PRA also hired approximately twelve (12) programmers employed by VHS who work in

India.

competitive with [PRA’s] business” or “which may (i) interfere with [his] ability to

discharge [his] responsibilities” or “(ii) detract from [PRA’s] business or its goodwill

and reputation.” (Id.) The Employment Agreement further provides that

Parthasarathy may not:

(i) work on either a part-time or independent

contracting basis for any other company, business or

enterprise without the prior written consent of the

CEO; or

(ii) serve on the board of directors or comparable

governing body of any other material business, civic

or community corporation or similar entity without

the prior written consent of the CEO.”

(Id.)

D. The Development Milestones

17. The undisputed evidence in the record shows that neither Plaintiffs nor

PRA fully appreciated the difficulty of integrating CTMax into PRA’s clinical trial

management environment, and the optimistic schedule for implementation of the

new system envisioned by the parties quickly proved unattainable.

18. The attempt to integrate and implement CTMax into PRA proceeded in

fits and starts. In June 2015, Parthasarathy advised PRA that he believed his team

would be able to complete the deployment of the new CTMS at PRA within four to six

months, but they ultimately failed to do so. (ECF Nos. 111/113, at p. 5.) PRA then

set a series of new deadlines for completing the enhancements to CTMax and

implementing the integration of the software into PRA, but each of the deadlines

proved unachievable. (Id. at pp. 5–11.)

19. PRA subsequently changed the name of the new CTMS software it was

trying to implement to “Predictivv Study Operations” (“PSO”). PRA also decided to

“unmanage” the CTMax software package and to implement only certain

functionalities of CTMax into PRA’s clinical trial management environment rather

than trying to implement CTMax as a “managed” package. (Id.; Plfs.’ Br. Resp. to

PRA’s Mot. For SJ, ECF Nos. 125 [SEALED] and 133 [Public], at pp. 12–13.)

20. Over time, Shannon placed increasing importance and urgency on

completing the enhancements to PSO and implementing it within PRA. (ECF Nos.

111/113, at pp. 6–10; ECF Nos. 125/133, at pp. 11–12.) On August 2, 2016, PRA

circulated a directive from Shannon, advising that he expected increased urgency and

progress with developing PSO. The directive instructed the PSO project team to

promptly proceed with the implementation of PSO 3.0. (ECF Nos. 111/113, at pp. 6–

10.)

21. During the second half of 2016 and into 2017, PRA provided additional

resources and personnel towards completing the implementation of PSO into PRA.

In June 2016, PRA hired Deborah Jones-Hertzog (“Jones-Hertzog”) as the Senior VP

of IT and tasked her with pushing the PSO project to completion as soon as possible.

(Id.) PRA also restructured Parthasarathy’s role within PRA, removing his more

direct responsibilities for implementing PSO, and instead tasking him to consult with

the PSO project team and assist with preparing responses to customer Requests for

Proposals (RFP). (Id.)

22. It is undisputed that despite the efforts of Plaintiffs and PRA, the

Development Milestones were not achieved within the 18-month Integration Period

as required by the APA. PRA was not able to fully implement PSO in its clinical trial

management environment until April 2018. (ECF Nos. 125/133, at p. 16.)

E. Sales Milestones

23. Over the course of Parthasarathy’s employment, he and PRA discussed

and evaluated various potential avenues for selling CTMax, and later PSO, to

companies in the biotech and pharmaceutical industries. (ECF Nos. 111/113, at pp.

11–12.) However, PRA was unwilling to sell PSO before PRA had successfully

implemented it within its own clinical trial management environment. (ECF Nos.

125/133, at pp. 6–7.) Although Parthasarathy disagreed, he agreed that PRA would

“need to have confidence in the software it is selling to customers,” and that, if PRA

lacked such confidence, “that would be a legitimate business reason not to sell

CTMax.” (ECF No. 112.1, at pp. 74–75.)

F. The Takeda Master Service Agreement

24. Effective August 31, 2016, PRA entered into a Master Services

Agreement to provide services to Takeda Pharmaceuticals (“Takeda MSA”). (ECF

No. 113.1 [SEALED]; ECF No. 116.5, Ex. D [SEALED].) Under the terms of the

Takeda MSA, PRA agreed to provide certain “Services” to Takeda, including clinical

trial management services, using “PRAHS Owned Technology.” (ECF No. 116.5, Ex.

D p. 2.) (Section 3.01), and Exhibit 1 (Definitions).) The Takeda MSA granted Takeda

a “License to PRAHS Owned Technology” as follows:

Section 7.02(b) License to PRAHS Owned Technology

During the Term. As of the Commencement Date and for

the remainder of the Term, PRAHS hereby grants Takeda,

Takeda Affiliates and their respective Personnel and third

party service providers the right to access and use PRAHS

Owned Technology used in supporting or providing the

Services for purposes of receipt and use of the Services in

the conduct of Takeda’s and Takeda’s Affiliates’ business.

For the avoidance of doubt, the foregoing right is granted

under all PRAHS Owned IP and includes the right to use

all configuration capabilities offered by the PRAHS Owned

Technology.

“PRAHS Owned Technology” means (i) all confidential or

proprietary processes, procedures, methodologies,

standard operating procedures, software, templates,

programs, and other protectable materials that are used

generally by PRAHS in PRAHS’s business . . . (ii)

derivative works of item (i); and (iii) any form of delivery

for (i) and (ii) received as part of the Services, such as via

Cloud Computing.

(Id. at p. 20 of 66; Exhibit 1 at p. 8 of 14.)

25. The Takeda MSA defines Cloud Computing to include a concept known

as “software as a service” or “SaaS.” (ECF No. 116.6). PRA’s Rule 30(b)(6) corporate

witness for the Takeda transaction, Brian Haas, testified that “software as a service

means that the client does not have to own the technology, that they can basically

utilize whether through licensing or combined with a service in order to be provided

with access to that output or that use of the software or the instance.” (Haas 30(b)(6)

Dep., ECF No. 116.7, at p. 15.)

26. The Takeda MSA also includes an Exhibit titled “Approved Third Party

Technology” that lists the technology Takeda has approved for PRA to use in

providing the Services to Takeda. (ECF No. 116.5, at pp. 34–36.) Identified among

the list of “Third Party Software,” is the Solutions. (Id.) Specifically, Section 2(A) of

Exhibit 18 refers to the Solutions (or components or pieces of the Solutions) including

“PSO,” “Predictivv Connect” (Base and Plus), “Project Portal,” “PAWS,” “Resource

Management,” “Safety Case Tracker,” “Safety Letter Tracker,” “Predictivv Risk-

Based Monitoring Tool,” and “Predictivv Patient Recruitment Tool.” (Id.)

27. As discussed further below, Plaintiffs claim that the license granted to

Takeda as part of the Takeda MSA constitutes an “External Sale,” a term defined in

the APA, and that this license should be credited towards the Sales Milestones. PRA

earned “ten to twelve million” dollars under the Takeda MSA in 2016, “approximately

one hundred million” dollars in 2017, “a hundred and seventy million” in 2018, and

“approximately two hundred and eleven million” for 2019, for a total of approximately

$491 million dollars. (ECF No. 116.7, at p. 34.) PRA currently uses PSO (version 3.0)

to manage “approximately three to four” projects for Takeda under the Takeda MSA.

(Haas 30(b)(6) Dep., ECF No. 116.7, at p. 28.)

G. Discussions of Amendments to the Milestones

28. In December 2016, at Parthasarathy’s request, he and Shannon met to

discuss amending the APA to provide for new deadlines for achieving the Milestones.

Shannon subsequently asked Jones-Hertzog to work with PRA’s in-house counsel,

Chuck Munn (“Munn”), to develop an amended framework for the Milestones. Jones-

Hertzog and Irene worked on proposed terms of an amendment with Parthasarathy.

However, while draft proposed terms of an amendment were circulated between

Munn, Jones-Hertzog, and Irene, it is undisputed that they were never presented to

Parthasarathy. (ECF Nos. 111/113, at pp. 10–11 and 12–13.)

29. Plaintiffs allege that PRA “falsely promis[ed] to amend the APA and

extend the milestone deadlines” and “made representations to Mr. Parthasarathy

that induced him to believe that PRA intended to amend the payment milestone

timelines.” (ECF No. 60.1, at ¶¶ 104–05, 109.) More particularly, on February 8,

2017, Shannon sent an email to Parthasarathy stating that PRA was “obviously

trying to get [VHS and/or Mr. Parthasarathy] a contract” to address the milestone

timeline issue, and in or around May 2017, Jones-Hertzog communicated to

Parthasarathy that she had proposed revised milestone timelines internally with

PRA and was awaiting approval. (ECF No. 60.1, at ¶¶ 116–17.)

30. In July 2017, Parthasarathy sent his own proposal to PRA containing

his suggestions regarding amendments of the Development Milestones and proposals

for potential resolutions of the Sales Milestones. (Dep. Ex. 161, ECF No. 112.1, at pp.

781–786.) In the proposal, Parthasarathy asserted: i) that Milestone One had been

satisfied and “should be paid as soon as possible”; and ii) that Milestones Two and

Three “need[ed] to be rewritten” or, alternatively, PRA needed to identify what

additional work was needed from Parthasarathy so that those milestones could be

completed and paid by no later than January 2018. (Id.).

31. In his proposal, Parthasarathy also acknowledged that the first Sales

Milestone had not been achieved and proposed terms for a potential financial

settlement between Plaintiffs and PRA. (Id. at p. 785.) Parthasarathy proposed three

options for settlement: that PRA pay VHS “7 million as a onetime payment . . . as a

royalty to use the product”; that PRA pay VHS “2 million dollars . . . for four years”;

or that PRA pay $2.5 million “immediate[ly]” and transfer the software back to

Parthasarathy. (Id. at p. 786.)

32. Ultimately, PRA and Plaintiffs were not able to reach an agreement on

amending the Milestones.

H. My Game Solutions

33. Sometime in late 2016, unbeknownst to PRA, Parthasarathy launched

a mobile application for tennis players known as “My Game Solutions” (“MGS”).

(PRA’s Br. Opp. Pls.’ Mot. For SJ, ECF Nos. 122 [SEALED] and 120 [Public], at pp.

1–4.) Initially, Parthasarathy began work on MGS from his home, however,

sometime in August 2017, Parthasarathy opened an office space to conduct activities

related to MGS and hired paid employees to assist him with his work for MGS.

During late 2016 and 2017, Parthasarathy, who served as MGS’s President and CEO,

was involved in every aspect of the development of the application and the direction

of MGS’s employees. Parthasarathy also served on MGS’s board of directors but did

not inform PRA of his position on the MGS board. (Id.)

34. PRA claims that during 2017, Parthasarathy was “checked out of his

[PRA] responsibilities and duties.” (ECF No. 123, at p. 103; Dep. of Irene, at p. 116).

Jones-Hertzog stated that sometime in 2017, Parthasarathy was disengaged from his

job responsibilities, alleging that he would attend meetings without making any

comments and not reply to e-mails. (ECF No. 112.1, Dep. of Jones-Hertzog, Ex.7, at

p. 241.) Irene testified that Parthasarathy made a commitment “to dedicate his

efforts to PRA and not start other businesses while employed by PRA; that was the

commitment that he made,” and that Parthasarathy’s acceptance of compensation

from PRA while forming MGS is the basis of PRA’s breach of employment

counterclaim. (Dep. of Irene, at p. 117, 119.)

I. PRA Terminates Parthasarathy’s Employment

35. In or around June 2017, PRA retained a consulting firm to review its

progress in implementing PSO. Shannon had becomes disenchanted with

Parthasarathy and hoped to use the consultant’s conclusions as a basis for

terminating Parthasarathy’s employment. Shannon believed that terminating

Parthasarathy would conclude PRA’s obligations under the APA. (ECF Nos. 125/133,

at pp., at pp. 17–18.)

36. In late October 2017, PRA terminated Parthasarathy’s employment.

The parties do not provide information regarding the reasons for Parthasarathy’s

termination.

37. On February 9, 2018, PRA and Parthasarathy entered into a

Confidential Release and Settlement Agreement, pursuant to which the parties

agreed that Parthasarathy’s employment ended effective December 29, 2017.

(“Settlement Agreement,” ECF No. 116.9.) In the Settlement Agreement,

Parthasarathy agreed to release PRA from any employment-related claims, and PRA

agreed to pay Parthasarathy $117,618.75 as a severance payment. (Id. at p. 1.) In

further exchange for the payment, Parthasarathy “represent[ed] that, as of the date

of execution of this Agreement . . . (b) [he] has not breached any provision of the

Employment Agreement . . . .” (Id. at p. 5.) The release in the Settlement Agreement

expressly excludes claims “arising under or related to the APA,” (Id. at p. 3), and PRA

expressly agreed to “adhere to and honor . . . all obligations set forth in or arising out

of or related to the” APA. (Id. at p. 2.)

II. PROCEDURAL BACKGROUND

38. Plaintiffs filed the Complaint in this matter on October 5, 2018. (ECF

No. 5.) On November 15, 2018, this case was designated a mandatory complex

business case and assigned to the undersigned. (Designation Order, ECF No. 1;

Assignment Order, ECF No. 2.)

39. On November 1, 2019, the Court granted leave for Plaintiffs to file an

Amended Complaint. (Or. on Pls.’ Mot. to Am. Compl., ECF No. 74.) In the Amended

Complaint, Plaintiffs allege claims against PRA for: breach of contract (First Cause

of Action); intentional misrepresentation (Second Cause of Action); negligent

misrepresentation (Third Cause of Action); fraudulent inducement (Fourth Cause of

Action); violation of North Carolina’s Unfair and Deceptive Trade Practices Act,

N.C.G.S. § 75-1.1 (“UDTPA”) (mislabeled as the Sixth Cause of Action); promissory

estoppel (mislabeled as the Seventh Cause of Action); and unjust enrichment

(mislabeled as the Eighth Cause of Action). (ECF No. 60.1, ¶¶ 129–195.)

40. On March 26, 2019, PRA filed its Amended Answer, Affirmative

Defenses, and Counterclaims. (“Amended Counterclaims,” ECF No. 37.) PRA

brought counterclaims for: (1) breach of the APA against Parthasarathy and Value

Health; (2) fraudulent inducement against Parthasarathy and Value Health; (3)

negligent misrepresentation against Parthasarathy and Value Health; (4) breach of

the Employment Agreement and Settlement Agreement against Parthasarathy; and

(5) tortious interference with contractual relations against Parthasarathy. (Id.)

Plaintiffs filed a Motion to Dismiss seeking dismissal of Defendants’ counterclaims

pursuant to Rule 12(b)(6) of the North Carolina Rules of Civil Procedure. (ECF No.

41.) Following briefing and a hearing, the Court dismissed PRA’s counterclaims for

breach of the APA against Parthasarathy and Value Health, fraudulent inducement

against Parthasarathy and Value Health, and negligent misrepresentation against

Parthasarathy and Value Health. (ECF No. 61.) PRA subsequently filed a Voluntary

Dismissal of its counterclaim for tortious interference with contractual relations

against Parthasarathy. (ECF No. 86.) The sole counterclaim that remains is Count

IV of the Amended Counterclaim for Breach of Contract Against Parthasarathy.

(ECF No. 37, at p. 32.)

41. PRA filed a motion to dismiss seeking the dismissal of all of Plaintiffs’

claims except for the breach of contract claim pursuant to Rule 12(b)(6) of the North

Carolina Rules of Civil Procedure (“Rules”) (ECF No. 77.) Following briefing and a

hearing, the Court issued an Order and Opinion granting the motion to dismiss to

the extent it sought dismissal of Plaintiffs’ claims for: intentional misrepresentation

(fraud) and fraudulent inducement that were based on alleged pre-APA

misrepresentations except for those fraud and fraudulent inducement claims based

on alleged misrepresentations in the LOI; intentional misrepresentation (fraud) and

fraudulent inducement based on alleged omissions from the LOI; negligent

misrepresentation; promissory estoppel; and unjust enrichment. (ECF No. 106 at pp.

31–32.)

42. The four remaining claims in Plaintiffs’ Amended Complaint are:

Breach of Contract (Count I); Intentional Misrepresentation (Count II); Fraudulent

Inducement (Count IV); and Violation of the North Carolina Unfair and Deceptive

Trade Practices (“UDTPA”), N.C.G.S. § 75-1.1 (Count VI) (Id.) Defendants move for

Summary Judgment on each of these four claims. (ECF No. 110, at p. 2.) PRA filed

its Brief in Support of Motion for Summary Judgment on June 12, 2020. (ECF No.

111.) Plaintiffs filed their Response to PRA’s Motion for Summary Judgment on

August 11, 2020. (ECF No. 125.) PRA filed a Reply in Support of Motion of Summary

Judgment on September 10, 2020. (ECF No. 129.)

43. Plaintiffs move for summary judgment on: (1) PRA’s sole-remaining

counterclaim of breach of contract against Parthasarathy (ECF No. 116 at p. 1; ECF

No. 37, at p. 22); and (2) the contention that Takeda MSA qualifies as an External

Sale under the APA. (ECF No. 116, at p. 2.) Plaintiffs filed an Opening Brief in

Support of their Motion for Summary Judgment. (ECF No. 116.) PRA filed a Brief

in Opposition to Plaintiffs’ Motion for Summary Judgment (ECF No. 120), Plaintiffs

filed their Reply in Support of their Motion for Summary Judgment. (ECF No. 128).

44. Plaintiffs and PRA also filed numerous sets of evidentiary materials in

support of and in opposition to the Motions.

45. The Court held a hearing on the Motions for Summary Judgment at

which counsel presented arguments. The Motions for Summary Judgment are now

ripe for disposition

III. ANALYSIS

A. Standard of Review

46. “The purpose of summary judgment is to dispense with formal trials in

cases where only legal issues remain ‘by permitting penetration of an unfounded

claim or defense in advance of trial and allowing summary disposition for either party

when a fatal weakness in the claim or defense is exposed.’” Miller v. Rose, 138 N.C.

App. 582, 585–86 (2000) (citation omitted). “Summary judgment is appropriate ‘if the

pleadings, depositions, answers to interrogatories, and admissions on file, together

with affidavits, if any, show that there is no genuine issue as to any material fact and

that any party is entitled to judgment as a matter of law.’” Variety Wholesalers, Inc.

v. Salem Logistics Traffic Servs., LLC, 365 N.C. 520, 523 (2012) (quoting N.C.G.S. §

1A-1, Rule 56(c)). The moving party bears the burden of presenting evidence which

shows that there is no genuine issue of material fact and that the movant is entitled

to judgment as a matter of law. Hensley v. Nat’l Freight Transp., Inc., 193 N.C. App.

561, 563 (2008). The moving party may meet this burden by “proving an essential

element of the opposing party’s claim does not exist, cannot be proven at trial, or

would be barred by an affirmative defense.” Variety Wholesalers, Inc., 365 N.C. at

523. An issue is “material” if “resolution of the issue is so essential that the party

against whom it is resolved may not prevail.” McNair v. Boyette, 282 N.C. 230, 235

(1972). “A ‘genuine issue’ is one that can be maintained by substantial evidence.”

Dobson v. Harris, 352 N.C. 77, 83 (2000).

47. Once the movant presents evidence in support of the motion, the

nonmovant “cannot rely on the allegations or denials set forth in her pleading [ ] and

must, instead, forecast sufficient evidence to show the existence of a genuine issue of

material fact in order to preclude an award of summary judgment.” Steele v. Bowden,

238 N.C. App. 566, 577 (2014) (internal citation omitted). In conducting its analysis,

the Court must view the evidence in the light most favorable to the nonmovant.

Dobson, 352 N.C. at 83.

48. In determining whether the non-movant has met its burden in opposing

a motion for summary judgment, the judge “unavoidably asks whether reasonable

jurors could find by a preponderance of the evidence that the plaintiff is entitled to a

verdict[.]” Sloan v. Miller Bldg. Corp., 119 N.C. App. 162, 165–66

(1995) (quoting Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 252–55

(1986)) (quotations and emphasis omitted). As recently reiterated by the North

Carolina Court of Appeals, the burden on the non-movant goes beyond merely

producing some evidence, or a scintilla of evidence, in support of its claims. Rather,

[i]f the movant meets [its] burden, the nonmovant must

take affirmative steps to set forth specific facts showing the

existence of a genuine issue of material fact. . . . A genuine

issue of material fact is one that can be maintained by

substantial evidence. Substantial evidence is such

relevant evidence as a reasonable mind might accept as

adequate to support a conclusion and means more than a

scintilla or a permissible inference.

Khashman v. Khashman, 255 N.C. App. 449 (Sept. 5, 2017) (unpublished) (citations

and quotation marks omitted). In summary, this Court must decide “not whether

there is literally no evidence, but whether there is any upon which a jury could

properly proceed to find a verdict for the party producing it, upon whom the onus of

proof is imposed.” Anderson, 477 U.S. at 251.

49. The Court will first address PRA’s Motion and then Plaintiffs’ Motion.

B. PRA’s Motion

50. Defendants move for summary judgment on the four remaining claims

in Plaintiffs’ Amended Complaint: breach of the APA (Count I); intentional

misrepresentation (Count II); fraudulent inducement (Count IV); and violation of the

North Carolina Unfair and Deceptive Trade Practices (“UDTPA”), N.C.G.S. § 75-1.1

(Count VI).

1. Breach of the APA

51. Plaintiffs allege that PRA breached the express and implied terms of

the APA by failing to make the contingent payments to Plaintiffs for meeting the

Milestones. (ECF No. 60.1, at ¶¶ 129–33; ECF No. 125/133, at pp. 20–24.)

52. Preliminarily, the Court notes that the APA provides that Delaware law

shall apply to construction and enforcement of the agreement, and that Plaintiffs and

PRA argue that Delaware law is applicable to the claims for breach of the APA. “As

a general rule, North Carolina will give effect to a contractual provision agreeing to

a different jurisdiction’s substantive law.” Tanglewood Land Co. v. Byrd, 299 N.C.

260, 262 (1980) (“[W]here parties to a contract have agreed that a given jurisdiction's

substantive law shall govern the interpretation of the contract, such a contractual

provision will be given effect.”); Akzo Nobel Coatings Inc. v. Rogers, 2011 NCBC

LEXIS 42, at *21 (N.C. Super. Ct. Nov. 3, 2011). However, North Carolina courts will

not apply the chosen state’s law if “(a) the chosen state has no substantial relationship

to the parties or the transaction and there is no other reasonable basis for the parties’

choice, or (b) application of the law of the chosen state would be contrary to a

fundamental policy of [North Carolina].” Cable Tel Servs. v. Overland Contracting,

Inc., 154 N.C. App. 639 (2002) (applying North Carolina law to a contract dispute

despite a Colorado choice of law provision because there was no substantial

relationship between the parties or transaction to Colorado).

53. The Court concludes that Delaware law should be applied to the claim

for breach of the APA. First, PRA is a Delaware corporation which provides the

necessary substantial relationship between Delaware and the parties. (ECF No. 8.1

at APA, p. 1.) Akzo Nobel Coatings, Inc. v. Rogers, 2011 NCBC LEXIS 42, at *22 (N.C.

Super. Ct. Nov. 3, 2011) (finding “Delaware has a substantial relationship to the

transaction” where defendants’ contracts containing the Delaware choice of law

provision were with plaintiff, a Delaware corporation). Second, the Court has

reviewed the applicable law and concludes that applying Delaware law to the claim

for breach of the APA would not be contrary to any fundamental policy of North

Carolina.

54. Defendants seek summary judgment as to Plaintiffs’ claims that PRA

breached the APA by failing to make the contingent payments tied to the Milestones.

Under Delaware law, the elements of a breach of contract claim are: the existence of

a contract, the breach of an obligation imposed by that contract, and resulting

damages to the plaintiff. VLIW Tech., LLC v. Hewlett-Packard Co., 840 A.2d 606, 612

(Del. 2003). It is undisputed that the APA is a valid contract.

55. The Delaware Supreme Court has held

Delaware adheres to the objective theory of contracts, i.e.

a contract’s construction should be that which would be

understood by an objective, reasonable third party. We

read a contract as a whole and [ ] will give each provision

and term effect, so as not to render any part of

the contract mere surplusage.

When the contract is clear and unambiguous, we will give

effect to the plain meaning of the contract's terms and

provisions. On the contrary, when we may reasonably

ascribe multiple and different interpretations to a contract,

we will find that the contract is ambiguous. An

unreasonable interpretation produces an absurd result or

one that no reasonable person would have accepted when

entering the contract.

Estate of Osborn v. Kemp, 991 A.2d 1153, 1159–60 (Del. 2010) (internal citations and

quotations omitted). “The determination of ambiguity lies within the sole province of

the court.” Id. at 1160.

56. The Delaware Supreme Court has “upheld awards of summary

judgment in contract disputes where the language at issue is clear and unambiguous.

In such cases, the parol evidence rule bars the admission of evidence from outside the

contract's four corners to vary or contradict that unambiguous language.” GMG

Capital Invs., LLC v. Athenian Venture Partners I, L.P., 36 A.3d 776, 783 (Del. 2012)

(internal citations omitted). “But, where reasonable minds could differ as to the

contract's meaning, a factual dispute results and the fact-finder must consider

admissible extrinsic evidence. In those cases, summary judgment is improper.” Id.

The parties do not contend that the language in the Development Milestones

provisions of the APA is ambiguous or need interpretation.

a. Development Milestones

57. Significantly, Plaintiffs do not claim, and have not presented evidence,

that they fully achieved the Development Milestones as expressly set out in

Schedules 2.6(a)(i–iii) of the APA. Instead, Plaintiffs argue that PRA breached the

APA because: (a) PRA did not reasonably and in good faith determine the completion

of the Development Milestones in 2.6(a)(i) and 2.6(a)(ii); (b) PRA waived the

Development Milestones 2.6(a)(i) and 2.6(a)(ii); (c) VHS substantially performed the

Development Milestones in sections 2.6(a)(i) and 2.6(a)(ii); and (d) PRA improperly

conditioned Development Milestone 2.6(a)(iii) on achievement of the Development

Milestones in sections 2.6(a)(i) and 2.6(a)(ii). (ECF Nos. 125/133, at pp. 20–29.) PRA

challenges these contentions. (ECF No. 110, at pp. 3–4; ECF Nos. 113/111, at pp.

114–19; ECF No. 129, at pp. 1–8.) The Court takes each argument in turn.

58. Plaintiffs first argue that the failure to meet the Development

Milestones should be excused because PRA failed to exercise its discretion in

determining whether VHS had achieved those milestones reasonably and in good

faith, and that its “decision making was arbitrary and improperly motivated.” (ECF

Nos. 125/133, at pp. 20, 21–22.) Plaintiffs contend that: “PRA knew the ‘modules’ and

‘functions’ . . . had been in a constant state of flux”; “PRA applied different technical

definitions of completion from those agreed to, knowingly disregarded substantial

changes to the Salesforce® modules to be integrated, and failed to consider that the

software functions PRA required were ‘mostly code complete’”; and “PRA directly and

indirectly prevented the completion of the requirements.” (Id. at pp. 20–21.)

Plaintiffs also claim that PRA “failed to credit completion of new and different

[development] requirements.” (Id. at p. 22.)

59. In addition, Plaintiffs claim that in 2017, after the deadlines for

completing the Development Milestones had passed, PRA engaged in conduct

demonstrating “bad faith.” (Id. at pp. 21–22.) Plaintiffs allege that in late 2016, PRA

was “focused on extracting product knowledge” from Mr. Parthasarathy, as opposed

to reasonably assessing completion. (Id. at p. 21.) By 2017, PRA was “actively

deceiving Mr. Parthasarathy about amending the APA and was determined to

terminate his employment, mistakenly believing it would end PRA’s obligations

under the APA.” (Id. at pp. 21–22.)

60. Plaintiffs’ argument amounts to a claim that PRA breached an implied

duty of good faith and fair dealing under the APA. 5 Delaware will imply a covenant

of good faith and fair dealing to “honor the parties’ reasonable expectations” under

the contract. Dunlap v. State Farm Fire & Cas. Co., 878 A.2d 434, 447 (Del. 2005).

However, Delaware courts “will only imply contract terms when the party asserting

the implied covenant proves that the other party has acted arbitrarily or

unreasonably, thereby frustrating the fruits of the bargain that the asserting party

reasonably expected.” Nemec v. Shrader, 991 A.2d 1120, 1126 (Del. 2010). The

“implied covenant is a judicial convention designed to protect the spirit of an

agreement when, without violating an express term of an agreement, one side uses

oppressive or underhanded tactics . . . .” Chamison v. Healthtrust, Inc., 735 A.2d 912,

920 (Del. Ch. 1999), aff'd, 748 A.2d 407 (Del. 2000); see LSVC Holdings, LLC v.

Vestcom Parent Holdings, Inc., 2017 Del. Ch. LEXIS 865, *31 (2017).

61. The covenant of good faith “is not an equitable remedy for rebalancing

economic interests after events that could have been anticipated, but were not, [ ]

later adversely affected one party to a contract. Rather the covenant is a limited and

extraordinary legal remedy.” Nemec, 991 A.2d at 1128. The covenant will not be

implied “to give plaintiffs contractual protections that they failed to secure for

5 Indeed, the case authority cited by Plaintiffs in support of their argument, Gilbert v. El Paso

Co., 490 A.2d 1050 (Del.Ch. 1984), analyzed the issue as one falling under the implied

covenant of good faith and fair dealing. Id. at 1054–55.

themselves at the bargaining table.” Winshall v. Viacom Int'l, Inc., 55 A.3d 629, 636-

37 (Del. Ch. 2011). A court should not use the implied covenant to “rewrite a contract”

that a party “now believes to have been a bad deal.” Nemec, 991 A.2d at

1126. “Parties have a right to enter into good and bad contracts, the law enforces

both.” Id.

62. Once the Court determines that a “party has acted arbitrarily or

unreasonably,” Id., the task faced by a court in applying the covenant of good faith

and fair dealing as follows:

[T]he first step in evaluating an implied covenant claim is

to determine whether the contract in fact contains a gap

that must be filled. That is because the implied covenant

applies only if the contract is silent as to the subject at

issue. If the contract directly addresses the matter at

hand, existing contract terms control . . . such that implied

good faith cannot be used to circumvent the parties’

bargain. If, on the other hand, the express terms of the

contract do not address the subject at issue, the Court must

then consider whether implied contractual terms fill the

gap. The Court conducts that inquiry by asking whether it

is clear from what was expressly agreed upon that the

parties who negotiated the express terms of the contract

would have agreed to proscribe the act later complained of

as a breach of the implied covenant of good faith—had they

thought to negotiate with respect to that matter. The

Court does not derive implied obligations from its own

notions of justice or fairness. Instead, it asks what the

parties themselves would have agreed to had they

considered the issue in their original bargaining positions

at the time of contracting. The implied covenant therefore

operates only in that narrow band of cases where the

contract as a whole speaks sufficiently to suggest an

obligation and point to a result, but does not speak directly

enough to provide an explicit answer.

MHS Capital LLC v. Goggin, 2018 Del. Ch. LEXIS 151, *30–32 (May 10, 2018)

(quotations and citations omitted).

63. The Court notes that despite invoking the covenant of good faith and

fair dealing, Plaintiffs do not argue how the standards established by Delaware courts

apply to the facts in this case. For example, Plaintiffs do not identify any “gaps” in

the provisions of the APA that need to be filled, nor argue what terms the parties

“would have agreed to had they considered the issue in their original bargaining

positions at the time of contracting.” MHS Capital LLC, 2018 Del. Ch. LEXIS 151 at

*31 (citing Katz v. Oak Industries, Inc., 508 A.2d 873, 880 (Del. 1986)). Instead,

Plaintiffs take issue with various decisions made by PRA and complain that, in

retrospect, they seem unfair or arbitrary.

64. It is not clear in what way Plaintiffs contend PRA failed to reasonably

exercise its discretion in determining that the first Development Milestone as

outlined in Schedule 2.6(a)(i) had not been achieved. The first Development

Milestone required that CTMax be integrated into PRA’s Salesforce environment

within 18 months following the closing. While the evidence may show that pieces of

CTMax functionality were integrated into PRA within the 18-month period, it is

undisputed that full integration did not occur until approximately April 2018, almost

three years after the Closing. Plaintiffs have not created a disputed issue of fact that

PRA did not act reasonably and in good faith in determining that Plaintiffs failed to

meet the first Development Milestone.

65. Plaintiffs also contend that PRA acted unreasonably because it did not

consider that individual “key product enhancements” listed in the Second Milestone

(Schedule 2.6(a)(ii)) had been completed and that certain other enhancements were

eliminated by PRA as unnecessary. The evidence shows that some individual product

enhancements listed in Schedule 2.6(a)(ii) were completed before Parthasarathy’s

employment with PRA terminated, and that some of those enhancements were

accomplished within the required 18-month period following the Closing. The

evidence also shows that in implementing CTMax into PRA, PRA determined that at

least some of the product enhancements in Schedule 2.6(a)(ii) were not needed.

66. The evidence, however, does not support Plaintiffs’ contention that the

completion of some product enhancements and the elimination of others impeded

Plaintiffs’ achievement of the Second Milestone or that PRA unreasonably failed to

consider those facts in determining that Plaintiffs had not completed the second

Development Milestone.

67. Finally, Plaintiffs contend that after the deadlines for completing the

Development Milestones had passed, PRA engaged in conduct demonstrating that its

determinations as to the first and second Development Milestones were made in “bad

faith.” (ECF Nos. 125/133, at p. 21.) Plaintiffs claim that in late 2016 “PRA was

‘focused on extracting product knowledge’ from Mr. Parthasarathy, as opposed to

reasonably assessing completion.” (Id.) Plaintiffs also contend that “[b]y 2017, PRA

was actively deceiving [ ] Parthasarathy about amending the APA and was

determined to terminate his employment, mistakenly believing it would end PRA’s

obligations under the APA.” (Id. at pp. 21–22.)

68. Plaintiffs’ contention that PRA was “focused on extracting product

knowledge” is reference to a phrase contained in an email from Irene to Jones-Hertzog

sent in December 2016 discussing Irene’s review of the Milestones and his suggested

revisions for purposes of negotiating amendments to the Milestones with

Parthasarathy. (ECF No. 125.15.) The full sentence from Irene’s email provides as

follows: “Here are some thoughts – focused on extracting product knowledge (IP) and

relating to PRA’s environment for purposes of expedited implementation.” (Id.

(emphasis added).) Rather than suggesting bad faith, the email indicates Irene’s

desire to acquire knowledge about the Solutions from Parthasarathy in order to

incorporate them into PRA as quickly as possible.

69. The evidence supports Plaintiffs’ contention that in or about June or

July 2017, Shannon concluded that he wanted to terminate Parthasarathy’s

employment with PRA and believed that it would end PRA’s obligations under the

APA. The evidence also shows that PRA stopped communicating with Parthasarathy

about amending the Milestones in late July 2017 but did not inform him that PRA

would not further negotiate over the amendments. 6 However, after careful

consideration, the Court concludes this evidence does not raise an issue of disputed

fact that PRA did not act reasonably and in good faith in determining that Plaintiffs

failed to meet the first and second Development Milestones. Even if the conduct

involved suggests a lack of good faith by PRA in handling Parthasarathy’s

termination, it occurred well after the deadline for completing the first and second

Development Milestones as provided in the APA, and there is no evidence linking

Shannon’s decision regarding Parthasarathy’s termination with PRA’s

determinations that the Development Milestones had not been achieved.

6 As discussed below in relation to Plaintiffs’ claims for fraud, the Court has concluded that

PRA did not make affirmative misrepresentations to Plaintiffs regarding PRA’s intent to

amend the Milestones.

70. In summary, Plaintiffs’ evidence fails to raise an issue of fact as to PRA’s

reasonable exercise of its discretion in determining that Plaintiffs had not achieved

the first and second Development Milestones.

71. Plaintiffs next argue that PRA waived the deadlines for completing the

Development Milestones. (ECF Nos. 125/133, at p. 21.) Under Delaware law

[i]t is well settled . . . that a party may waive contractual

requirements or conditions. But, the standards for

demonstrating waiver -- the voluntary and intentional

relinquishment of a known right -- are quite exacting. The

doctrine implies knowledge of all material facts and an

intent to waive, together with a willingness to refrain from

enforcing those [ ] rights. Furthermore, the facts relied

upon to demonstrate waiver must be unequivocal.

Applying those principles, [Delaware courts] have held

that three elements must be demonstrated to invoke the

waiver doctrine: (1) that there is a requirement or condition

capable of being waived, (2) that the waiving party knows

of that requirement or condition, and (3) that the waiving

party intends to waive that requirement or condition.

Amirsaleh v. Bd. of Trade of N.Y., 27 A.3d 522, 529–30 (Del. 2011) (quotations and

citations omitted).

72. PRA argues that the APA requires that any waiver of its terms must be

in writing. (ECF No. 112.1, at p. 370, “No waiver by a party of any term, covenant,

representation or warranty contained herein shall be effective unless in writing.”)

PRA contends that the written documents relied on by Plaintiffs in support of their

waiver argument were internal communications between PRA officials regarding the

amendment negotiations after the Development Milestone deadlines had passed and

that the communications were never shared with Plaintiffs. (ECF Nos. 113/111, at

pp. 16–17.) PRA further argues that Plaintiffs have failed to create an issue of fact

as to whether PRA intentionally and voluntarily waived the Development Milestones.

(ECF No. 129, at p. 2.)

73. The Court has painstakingly reviewed the evidence cited by Plaintiffs in

support of their argument that PRA waived the deadlines for the Development

Milestones. First, the undisputed evidence shows that the written documents relied

upon by Plaintiffs were never shared with Plaintiffs and, therefore, cannot form the

basis for a claim of waiver. Second, the evidence simply does not raise a genuine

issue of fact that PRA intended to waive the Development Milestones. At best, the

evidence establishes that PRA engaged in various communications with

Parthasarathy about the possibility of amending the deadlines but fails to support

even an inference that PRA “unequivocal[ly]” waived any Milestones. Amirsaleh, 27

A.3d at 529.

74. Plaintiffs next contend that they have raised an issue of fact as to

whether PRA breached the APA because “there is adequate evidence of ‘substantial

performance’ of the first two [D]evelopment [M]ilestone requirements,” and cite in

support Gildor v. Optical Sols., Inc., 2006 Del. Ch. LEXIS 110, at *25 (Del. Ch. June

5, 2006). (ECF No. 125/133, at p. 21.) Plaintiffs argue that there is evidence that

some of the functionality required under sections 2.6(a)(i) and (ii) of the APA were

achieved. (Id.)

75. PRA contends that the theory of “substantial performance” is not

available to cure Plaintiffs’ failure to perform under the facts at issue. (ECF No. 129,

at p. 2.) Instead, PRA argues that Gildor and its progeny have applied the theory of

“substantial performance” to forgive a party’s failure to meet the express

requirements of a contract only when the question is whether a party has adequately

complied with notice provisions contained in an agreement, citing Vintage Rodeo

Parent, LLC v. Rent-a-Ctr., Inc., 2019 Del. Ch. LEXIS 87, *43–44 (Del. Ch. Mar. 14,

2019) (“[T]his Court has, at times, accepted substantial compliance with notice

provisions in lieu of literal compliance, when the circumstances so justified.”).

76. The Court agrees with PRA’s argument. The only reported Delaware

decisions that the Court has located have applied the substantial performance theory

only in the narrow circumstances dealing with notice requirements in contracts. See

e.g., Arneault v. Diamondhead Casino Corp., C.A. No. 16-989-LPS, 2019 U.S. Dist.

LEXIS 93108, *8-9, (D. Del. 2019). The Court concludes that the substantial

performance theory does not apply to Plaintiffs’ failure to meet the express

requirements of the Development Milestones in the APA.

77. Plaintiffs also contend that PRA breached section 2.6(b) of the APA by

improperly conditioning the achievement of the Development Milestone in 2.6(a)(iii)

and Sales Milestones “on PRA’s internal development of PSO.” (ECF Nos. 125/133,

at pp. 22–24.) Plaintiffs’ argument, however, is difficult to discern. Although section

2.6(b) unambiguously provides that PRA cannot make the payment for achievement

of any Milestone conditional on having completed a prior Milestone, Plaintiffs

contend that the provision also “bar[s] PRA from conditioning or sequencing the

completion of the [M]ilestones (or requirements within a [M]ilestone).” (Id. at p. 23.)

Plaintiffs do not cite to any evidence in the record in their argument to support this

claim (see id. at pp. 22–23), and it is not at all clear to the Court in what way Plaintiffs

contend PRA violated section 2.6(b).

78. PRA argues that section 2.6(b) only prohibits PRA from conditioning the

payments for achievement of a particular Milestone on having achieved a prior

Milestone, and that “[t]here is no evidence that . . . any of the milestones were

achieved. Thus, PRA did not have an obligation to pay any of the milestones, nor did

it improperly ‘condition’ payment of one milestone ‘upon the satisfaction of any

conditions precedent to’ another milestone.” (ECF Nos. 113/111, at p. 15.)

79. The Court has thoroughly considered Plaintiffs’ argument and concludes

that the terms of section 2.6(b) are unambiguous, and that Plaintiffs have failed to

create any issue of material fact that PRA breached section 2.6(b) of the APA.

b. Sales Milestones

80. Plaintiffs next argue that PRA “interfered” with achievement of the

Sales Milestones in breach of the implied covenant of good faith and fair dealing.

(ECF No. 125/133, at pp. 25–29.) Plaintiffs claim that there is

substantial evidence that PRA used ‘oppressive or

underhanded tactics’ that ‘thwarted’ [Plaintiffs’]

reasonable expectations and a ‘fair opportunity to

maximize’ the External Sales Earnout, such as by

intending to block competitors from having access to the

Solutions, preventing marketing of the Solutions and

rejecting specific customer opportunities, limiting and

eliminating qualifying license arrangements, exploiting

the Solutions for Takeda MSA to earn service revenue for

PRA but refusing to give VHS milestone credit, diverting

resources and changing operational priorities, and

repeatedly rejecting all External Sales proposals years

before the milestone period ended, limiting Mr.

Parthasarathy’s role and ultimately terminating his

employment to try to escape the APA earnout obligations.

(Id. at pp. 28–29; quotations omitted.) Plaintiffs, however, do not cite to specific

record evidence or discuss the evidence supporting these claims in this portion of their

argument in their brief (Id. at pp. 25–29), and it is not clear to the Court upon what

evidence Plaintiffs base some of these alleged actions by PRA.

81. In order to decide if the covenant of good faith and fair dealing should

be applied, the Court must decide whether PRA “has acted arbitrarily or

unreasonably, thereby frustrating the fruits of the bargain that [Plaintiffs]

reasonably expected,” Nemec, 991 A.2d at 1126, and if so, “determine whether the

contract in fact contains a gap that must be filled.” MHS Capital LLC, 2018 Del. Ch.

LEXIS 151 at *30–32. “[T]he implied covenant applies only if the contract is silent as

to the subject at issue . . . [i]f, on the other hand, the express terms of the contract do

not address the subject at issue, the Court must then consider whether implied

contractual terms fill the gap.” Id. However, the existence of “gap” does not

automatically require application of the implied covenant. Instead, the Court must

decide if the missing term is one that the parties did not, and could not have,

anticipated in negotiating the APA. “The implied covenant of good faith and fair

dealing involves a ‘cautious enterprise,’ inferring contractual terms to handle

developments or contractual gaps that the asserting party pleads neither party

anticipated,” Nemec, 991 A.2d at 1125, and is not a means for creating “contractual

protections that ‘they failed to secure for themselves at the bargaining table.”

Winshall, 76 A.3d at 816 (internal quotation omitted); see also Allied Capital Corp. v.

GC-Sun Holdings, L.P., 910 A.2d 1020, 1035 (Del. Ch. 2006) (“[C]ourts should be most

chary about implying a contractual protection when the contract easily could have

been drafted to expressly provide for it.”). Only if the missing term is one the parties

could not have anticipated will the Court provide an implied term.

82. Plaintiffs do not specifically identify the “gaps” in the APA that the

implied covenant must fill. Further, Plaintiffs do not address whether the parties

negotiated about or considered the missing term and, if not, why the parties could not

have anticipated the issue involved in the missing term. Plaintiffs also do not explain

“what the parties themselves would have agreed to had they considered the issue in

their original bargaining positions at the time of contracting.” MHS Capital LLC,

2018 Del. Ch. LEXIS 151, at *30–32. Instead, they contend only that PRA’s actions

were arbitrary or unfair.

83. Plaintiffs first contend that PRA interfered with the achievement of the

Sales Milestones because it acquired Plaintiffs’ software “to block competitors from

having access to the Solutions.” (ECF Nos. 125/133, at p. 28.) Plaintiffs do not

explain how PRA’s motivations for entering into the APA with Plaintiffs could be

characterized as a breach of covenant of good faith in performing under the APA.

Nevertheless, the Court has thoroughly reviewed the evidence presented by Plaintiffs

and concludes that, at worst, it suggests that one of the reasons PRA believed it would

be advantageous to acquire the Solutions was because PRA believed it was promising

technology and wanted to purchase it to prevent its competitors from acquiring the

technology. In other words, PRA appears to have had a legitimate business interest

in acquiring PRA’s technology.

84. In addition, there is no contractual gap regarding this issue. To the

contrary, in the preamble paragraphs in the APA, the parties expressly acknowledge

Plaintiffs’ “desire” to sell to PRA, and PRA’s desire to purchase, “the Solutions and

substantially all of the assets of [Plaintiffs]” related to Plaintiffs’ business of

“provid[ing] cloud based solutions for the clinical trial process.” (ECF No. 112.1, at p.

349.) The implied covenant of good faith is not applicable to this issue.

85. Plaintiffs next argue that PRA violated a duty of good faith and fair

dealing by “preventing marketing of the Solutions and rejecting specific customer

opportunities, [and] limiting and eliminating qualifying license arrangements.” (Id.)

While Plaintiffs presented evidence that PRA refused to let Parthasarathy attempt

to sell CTMax/PSO to two potential customers (ECF Nos. 125/133, at pp. 6–7, 10–11,

and 16), PRA counters with evidence that it prevented Plaintiffs from selling the

Solutions because it had not yet implemented PSO within PRA and lacked confidence

that it could support the software until it was using it itself and was not yet prepared

to expend the extensive resources necessary to sell and support PSO to third-party

customers. (ECF No. 129, at pp. 3, 5–7.) Parthasarathy conceded that PRA’s lack of

confidence in PSO was a legitimate reason not to begin selling it to PRA’s customers.

(ECF No. 112.1, at pp. 74–75.)

86. Again, after careful review of the evidence in the record, the Court

concludes that no reasonable fact finder could conclude that PRA prevented sales of

PSO to specific customers to impede Plaintiffs from achieving External Sales, and

Plaintiffs’ argument is not supported.

87. Plaintiffs contend that PRA breached an implied duty of good faith by

“exploiting the Solutions for Takeda MSA to earn service revenue for PRA but

refusing to give VHS milestone credit.” (ECF Nos. 125/133, at p. 28.) Plaintiffs argue

that the licensing arrangement in the Takeda MSA in which PRA granted Takeda a

license to use PRA’s software in conjunction with managing clinical trials for Takeda

(“Takeda license”) should be credited to Plaintiffs as an “External Sale” of the

Solutions under APA. (ECF Nos. 116/117.1, at pp. 13–16.) 7 Plaintiffs contend that

PRA’s failure to treat the license to Takeda as an “External Sale” violates an implied

duty of good faith and fair dealing. Plaintiffs do not expressly address how the

current definition of “External Sale” has a gap, or whether they did, or should have,

anticipated the need to further clarify the definition of “External Sale” in negotiating

the APA.

88. In this instance, however, it is not significant because the Court has

thoroughly considered the record and concludes that there is insufficient evidence to

create an issue of fact that PRA acted unreasonably or arbitrarily in failing to credit

the Takeda license as an “External Sale” of the Solutions. To the contrary, Plaintiffs

did not contend that the Takeda license should be counted as an “External Sale” until

after this lawsuit was filed, and first raised the claim in the Amended Complaint. As

discussed below, Plaintiffs and PRA have offered differing interpretations of the scope

of the term “External Sales.” Accordingly, the Court concludes that there is no issue

of fact and, as a matter of law, PRA did not violate an implied covenant of good faith

in failing to treat the license to Takeda as an “External Sale.”

89. Plaintiffs also argue that PRA breached a covenant of good faith and fair

dealing by “diverting resources and changing operational priorities” and “limiting Mr.

Parthasarathy’s role and ultimately terminating his employment,” thereby

7 Plaintiffs’ contention that the Takeda MSA constitutes an “External Sale” for purposes of

achieving the Sales Milestones is an issue raised in Plaintiffs’ Motion and is considered below

in conjunction with decision of that motion.

interfering with achievement of the Sale Milestones. (ECF Nos. 125/133, at pp. 28–

29.) PRA contends that, to the extent Plaintiffs now complain that PRA did not give

Parthasarathy sufficient control over, and did not devote sufficient resources to,

achieving the Milestones, Plaintiffs “could have insisted on specific contractual

commitments from PRA about the issues . . . , including the level of resources devoted

to developing CTMax, a guarantee that Parthasarathy would have ‘full authority’

over the development, or a plan for making external sales.” (ECF Nos. 113/111, at p.

17 (citing Airborne Health, Inc. v. Squid Soap, LP, 984 A.2d 126, 145–47 (Del Ch.

Nov. 23, 2009) (“These provisions are familiar to any transactional lawyer, and [VHS]

was a sophisticated party represented by able counsel.”)).) PRA argues that “‘[t]he

implied covenant of good faith and fair dealing cannot properly be applied to give the

Plaintiffs contractual protections that ‘they failed to secure for themselves at the

bargaining table,’” quoting Winshall, 76 A.3d at 816. Finally, Defendants argue that

the evidence does not support a claim that PRA intentionally attempted to deprive

Plaintiffs of the ability to achieve the Milestones. (ECF Nos. 113/111, at pp. 18–19.)

90. Again, the Court finds that Plaintiffs could and should have bargained

for terms requiring PRA to provide certain levels of resources and for Parthasarathy’s

control over achievement of the Sales Milestones. In a case in which the defendant

argued the plaintiff breached a duty of good faith by failing to devote sufficient

resources to meeting incentive sales objectives, the Delaware Chancery Court held:

[Defendant]’s position is also undercut by the ease with

which [Defendant] could have insisted on specific

contractual commitments from [Plaintiff] regarding the

expenditure of resources, or some form of “efforts”

obligation for [Plaintiff]. These provisions are familiar to

any transactional lawyer, and [Defendant] was a

sophisticated party represented by able counsel. Moreover,

Section 7.6, entitled “Obligations of Seller,” provides that

“[e]ach Selling Partner agrees to take all reasonable

actions necessary to cause Seller to perform its obligations

hereunder and to otherwise comply with the terms of this

Agreement.” [Defendant] could have insisted on a

provision binding [Plaintiff]. Rather than holding out for

these types of contractual protections, [Defendant]

accepted earn-out provisions that are expressly phrased in

conditional terms.

Airborne Health, Inc., 984 A.2d at 147. The implied covenant should not be applied

here to create obligations on PRA that Plaintiffs should have obtained at the

bargaining table.

91. The same holds true for Plaintiffs’ claim that PRA terminated

Parthasarathy to interfere with his ability to achieve the Sales Milestones.

Parthasarathy, with assistance of counsel, negotiated a comprehensive Employment

Agreement in which he agreed to accept at-will employment with PRA. There is no

reason that Parthasarathy should not have anticipated the need to negotiate

appropriate protections for himself against PRA terminating his employment before

he had an opportunity to achieve the Milestones. He did not do so, and this Court

cannot now provide him this protection under the guise of implying a duty of good

faith.

92. In sum, the Court finds that Plaintiffs have failed to establish that

PRA’s so-called “interference” with, and failure to devote sufficient resources to,

achievement of the Sales Milestones involved issues that Plaintiffs could not have

anticipated in negotiating the APA and Employment Agreement.

93. Finally, the Court again has exhaustively studied the evidence in the

record and concludes that Plaintiffs simply do not raise a genuine issue of material

fact regarding whether PRA used underhanded or oppressive tactics to prevent

Plaintiffs from achieving the Sales Milestones. In deciding whether Plaintiffs have

met their burden in opposing PRA’s Motion, this Court must decide “not whether

there is literally no evidence, but whether there is any upon which a jury could

properly proceed to find a verdict for the party producing it, upon whom the onus of

proof is imposed.” Anderson, 477 U.S. at 251. Plaintiffs’ evidence is not sufficient for

a reasonable factfinder to conclude that PRA unlawfully interfered with achievement

of the Sales Milestones.

94. Therefore, to the extent PRA seeks summary judgment on Plaintiffs’

claims for breach of the APA, PRA’s Motion should be GRANTED.

2. Intentional Misrepresentation and Fraudulent Inducement

95. Plaintiffs bring claims for intentional misrepresentation and fraudulent

inducement. (ECF No. 60.1, at ¶¶ 134–46 and 157–72.) The Court’s Order on

Defendants’ Motion to Dismiss left for determination only: (1) Plaintiffs’ claims for

“intentional misrepresentation (fraud) and fraudulent inducement based on the

alleged post-APA misrepresentations by Shannon and Jones-Hertzog about PRA’s

intent to modify the APA,” (ECF No. 106, at pp. 17–18); and (2) Plaintiffs’ claim that

PRA made fraudulent misrepresentations in the LOI. (Id. at pp. 17–20.)

a. Alleged misrepresentations by Shannon and Jones-Hertzog

96. VHS alleges that “[o]n or around February 8, 2017, PRA’s CEO, Colin

Shannon, sent an email to Mr. Parthasarathy stating that PRA was ‘obviously trying

to get [VHS and/or Mr. Parthasarathy] a contract’ to address the milestone timeline

issue” and that “[i]n or around May 2017, Ms. Jones-Hertzog represented to Mr.

Parthasarathy that she had proposed a revised timeline internally and was awaiting

approval.” (ECF No. 60.1, at ¶¶ 116–17.) Plaintiffs further allege that despite these

representations, “PRA [ ] did not intend to . . . amend the terms of the APA to extend

the time for it to do so” (Id. at ¶ 124), and “knew its representations to be false when

it made them.” (Id. at ¶ 143.) Plaintiffs also allege that Parthasarathy relied on the

misrepresentations that PRA would modify the milestones to continue assisting PRA

with development of the Solutions. (Id. at ¶¶ 115, 120.)

97. In order to establish a claim for fraud or fraudulent inducement, a

plaintiff must prove: (1) false representation or concealment of a material fact, (2)

reasonably calculated to deceive, (3) made with intent to deceive, (4) which does in

fact deceive, (5) resulting in damage to the injured party. Ragsdale v. Kennedy, 286

N.C. 130 (1974). 8

98. To qualify as an intentional misrepresentation for purposes of a fraud

claim, the misrepresentation must be "definite and specific." Libby Hill Seafood

Restaurants, Inc. v. Owens, 62 N.C. App. 695, 698 (1983). “An unfulfilled promise is

not actionable fraud, however, unless the promisor had no intention of carrying it out

at the time of the promise, since this is a misrepresentation of a material fact.”

McKinnon v. CV Indus., 213 N.C. App. 328, 338 (2011).

99. PRA argues that “Colin Shannon’s February 2017 statement was in fact

true that PRA was ‘trying to get’ Plaintiffs a contract amendment,” and “there is no

evidence that [ ] Shannon acted with a fraudulent intent” via his February 2017

email. (ECF Nos. 113/111, at pp. 25–27.) PRA contends that mere failure to

8 The parties have not discussed which state’s substantive law applies to the fraud claims,

but make their arguments based on North Carolina law. Generally, North Carolina applies

a lex loci to determine the law that governs tort claims such as fraud. Harco Nat’l Ins. Co. v.

Grant Thornton LLP, 206 N.C. App. 687, 692 (2010) (“Our traditional conflict of laws rule is

that matters affecting the substantial rights of the parties are determined by lex loci, the law

of the situs of the claim . . . . For actions sounding in tort, the state where the injury occurred

is considered the situs of the claim.”); Camacho v. McCallum, 2016 NCBC LEXIS 81, at *17

(N.C. Super. Ct. Oct. 25, 2016) (“The place of the injury is the state where the injury or harm

was sustained or suffered—the state where the last event necessary to make the actor liable

or the last event required to constitute the tort takes place, and the substantive law of that

state applies.”). It is unclear from the evidence, and the parties do not indicate to the Court,

where Parthasarathy was physically located when the LOI was executed. Given there is

some indication that Parthasarathy was situated in New York, the Court has reviewed New

York law on fraudulent inducement. Hogan Willig, PLLC v. Kahn, 145 A.D.3d 1619, 1620–

21, (2016) (stating “[t]he elements of a fraud cause of action consist of a misrepresentation

or a material omission of fact which was false and known to be false by [the] defendant, made

for the purpose of inducing the other party to rely upon it, justifiable reliance of the other

party on the misrepresentation or material omission, and injury.” (internal citations

omitted)). The Court finds the law on fraud in New York to be substantively similar to North

Carolina’s law. Therefore, the Court conducts its analysis under North Carolina law.

ultimately agree on amendments to the Milestones does not prove that Shannon’s

statement was fraudulent. Id.

100. Defendants also argue that Jones-Hertzog’s representations were not

false because Chuck Munn, PRA’s in-house counsel, had in fact received a draft of the

proposed amendments from Jones-Hertzog. (Id. at pp. 27–28.)

101. The Court has reviewed the relevant evidence presented by the parties

and concludes that Plaintiffs have failed to produce substantial evidence to create an

issue of fact that Shannon’s and Jones-Hertzog’s statements were not true at the time

they were made or that the statements were intended to mislead Parthasarathy.

Dobson, 352 N.C. at 83 (“A ‘genuine issue’ is one that can be maintained by

substantial evidence.”). Instead, the evidence establishes that PRA engaged in

several months of negotiations with Parthasarathy regarding potential amendment

of the Milestones, but that ultimately the parties failed to reach agreement on the

amendments. (ECF Nos. 113/111, at pp. 25–28.)

102. Therefore, to the extent PRA’s Motion seeks summary judgment on

Plaintiffs’ claims of intentional misrepresentation and fraudulent inducement based

on statements made by Shannon and Jones-Hertzog, PRA’s Motion should be

GRANTED.

b. Alleged fraudulent misrepresentations in the LOI

103. In its Order and Opinion on Defendants’ Motion to Dismiss Amended

Complaint, the Court dismissed Plaintiffs’ claims for fraud based on omissions from

the LOI, but held that

the Court notes that PRA has not argued, and the Court

does not consider at this time, whether representations

contained within a letter of intent executed between two

businesses as part of arms-length negotiations can form

the basis for a claim for fraud or negligent

misrepresentation. The Court has serious questions about

the viability of such a claim under North Carolina law, and

PRA is not prohibited from making such an argument at

another appropriate time in this case. Nevertheless, the

Court addresses the arguments that PRA does raise.

Value Health Sols. Inc. v. Pharm. Research Assocs., 2020 NCBC LEXIS 65, *20-21,

(N.C. Super. Ct. May 22, 2020). PRA now moves for summary judgment as to

Plaintiffs’ claims for fraud based on alleged affirmative misrepresentations in the

LOI.

104. In the Amended Complaint Plaintiffs allege as follows:

158. VHS and Mr. Parthasarathy agreed to enter into the

APA for a relatively small closing payment in reliance on

PRA’s representations about the existence of a reasonable

opportunity to complete the milestones and receive the

fixed and variable milestone payments based on the

expressed management priorities and development

strategy of PRA.

159. After closing, however, as described above, it became

apparent that PRA’s representations were false and that a

reasonable opportunity to complete the milestones did not

exist.

(ECF No. 60.1, at ¶¶ 158–59.)

105. Plaintiffs further allege that “PRA knew its representations were false

at the time they made them. PRA did not intend to complete the software and sales

milestones set forth in Section 2.6 of the APA or to make the fixed and variable

milestone payments.” (Id. at ¶¶ 162–63.)

106. Referring to the language in the LOI that “the ability to earn [the Sales

Milestone payments] will last for the first [2, 3, and 4] fiscal years following the closing

date,” Plaintiffs contend that “PRA’s statement of intentions in the LOI was false” and

“PRA did not intend for VHS to have any ‘ability’ to earn the External Sales

milestone[s] for the ‘full’ anniversary periods stated.” (ECF Nos. 125/133, at pp. 29–

30.) Plaintiffs argue that PRA’s lack of intention to provide Plaintiffs with the ability

to earn the Sales Milestones is supported by evidence, inter alia, that: a presentation

to PRA’s board of directors in December 2014 revealed that PRA did not intend to

immediately “launch[ ]” CTMax “as a CTMS solution”; PRA acquired the Solutions to

“block” competing CROs from obtaining the Solutions; an internal PRA financial

analysis showed projections in which no income was generated from External Sales;

the so-called Siebel CTMS software “piracy” issue; and PRA’s alleged plan to use the

components of the Solutions but not allow Plaintiffs to make sales. (ECF Nos. 125/133,

at pp. 2–5, 29.)

107. PRA argues that a non-binding LOI cannot form the basis for a fraud

claim. (ECF Nos. 113/111, at p. 24). PRA contends that the LOI is titled “non-

binding” and contains express language stating: the LOI merely “outlines [PRA’s]

thinking regarding the possible structure of a Transaction”; that “none of this LOI,

any proposal made to the [Plaintiffs], nor the current on-going discussions between

the parties are intended to (and shall not) create a legally binding obligation or

commitment”; that the “Proposed Terms”—including the statement about Plaintiffs’

“ability to earn” consideration based on external sales—are just that: non-binding,

“proposed” terms, which, following due diligence, may be captured in a “definitive

agreement to be finalized”; and that “any business decision either party makes in

anticipation of ” a final agreement “is at the sole risk of the party making the

decision.” (Id. at pp. 24–25.) In support of its argument, PRA cites Triad Packaging,

Inc. v. SupplyOne, Inc., 597 Fed. App’x 734, 739-40 (4th Cir. 2015) (applying North

Carolina law and holding that a party’s statements regarding the sale price and

closing date in a non-binding letter of intent were “classic projections, exemplified by

the letter’s non-binding nature” and “cannot, therefore, form the basis of a fraud

claim”).

108. The Court has provided the elements of a claim for fraud above. In

addition to establishing fraud, there must be evidence of a misrepresentation of

existing or ascertainable fact, as distinguished from a matter of opinion or

representation relating to future prospects. Ragsdale, 286 N.C. at 139 (citing Berwer

v. Insurance Co., 214 N.C. 554 (1938)); Cash Register Co. v. Townsend, 137 N.C. 652

(1905); see also Williams v. Williams, 220 N.C. 806, 810 (1942) (stating that mere

unfulfilled promises cannot be the basis of a fraud claim unless the promisor had no

intention of carrying out the promise at the time it was made and that proof of non-

performance is not sufficient to establish the necessary fraudulent intent).

109. The Court has considered the evidence and the arguments of the parties

and concludes that Plaintiffs have failed to establish an issue of material fact, and

PRA is entitled to summary judgment on Plaintiffs’ claims for fraud and fraud in the

inducement arising from the representation that Plaintiffs would have “the ability to

earn” the Sales Milestone payments. First, the Court does not believe that the

contents of the LOI can form the basis for a fraud claim under the facts present in

this lawsuit. The LOI contains fulsome disclaimers making it clear that its contents

should not be relied upon by any party to the transaction, and that any reliance on

its terms are solely at the relying party’s risk. Under North Carolina law, letters of

intent that are expressly non-binding and contemplate a more detailed future

agreement between the parties are not binding agreements. E.g., Regency Ctrs.

Acquisition, LLC v. Crescent Acquisitions, LLC, 2018 NCBC LEXIS 7, *13–14 (Jan.

24, 2018); JDH Capital, LLC v. Flowers, 2009 NCBC LEXIS 8, at *15 (N.C. Sup. Ct.

Mar. 13, 2009) (finding that the letter of intent at issue was not a binding contract

because it, inter alia, stated on its face that it was a “letter of intent and that it is not

binding,” “contemplate[d] the execution of a more complete agreement,”

and contained “no language inferring an intent to be bound”) (citing Durham Coca-

Cola Bottling Co. v. Coca-Cola Bottling Co. Consol., 2003 NCBC LEXIS 5, at **23,

32–33 (N.C. Super. Ct. Apr. 28, 2003)); see also Boyce v. McMahan, 22 N.C. App. 254,

258 (1974) (holding that the agreement at issue was “made [ ] subject to a more

detailed agreement at some specific date to be agreed to by the parties hereto” and

was therefore not a binding contract) (internal quotation marks omitted).

110. Second, the “ability to earn” language relied on by Plaintiffs is, by its

very nature, a statement of future intent or a “representation relating to future

prospects.” Ragsdale, 286 N.C. at 139. Notably, this language did not make it into

the final APA, which is silent as to Plaintiffs’ ability to earn the Sales Milestones.

(ECF No. 112, at p. 352.)

111. Third, almost all the evidence upon which Plaintiff relies to establish

PRA’s fraudulent intent is from after the execution of the LOI in October 2014. In

particular, the board of directors meeting in which Plaintiffs claim PRA disclosed its

alleged plans not to sell the Solutions and its intent to block competitors from

acquiring the Solutions took place in December 2014, which was two months after

the LOI was executed. Plaintiffs have not produced substantial evidence that raises

an issue of material fact regarding PRA’s intent at the time it entered into the LOI.

112. Finally, Plaintiffs cite no authority from North Carolina or other

jurisdictions, and the Court was not able to locate any, in which a court has

recognized a claim for fraud arising out of representations contained in a letter of

intent. This clearly is not the case in which this Court should consider recognizing

such a claim.

113. Therefore, to the extent PRA’s Motion seeks summary judgment on

Plaintiffs’ claims of intentional misrepresentation and fraudulent inducement based

on representations contained in the LOI, PRA’s Motion should be GRANTED.

3. Violation of UDTPA

114. Plaintiffs’ claim for violation of the UDTPA is a repackaging of their

breach of contract and fraud claims. (ECF No. 60.1, at ¶¶ 173–78.) Plaintiffs allege

PRA engaged in unfair or deceptive practices by fraudulently inducing Plaintiffs to

enter into the APA, falsely promising to amend the Milestones, and by breaching the

APA by engaging in conduct to “interfere with, and prevent the completion of the

[M]ilestones.” (Id. at ¶ 175.) Here, Plaintiffs’ claim turns on whether they have

produced sufficient evidence of unfair or deceptive acts by PRA. Whether an act or

practice is unfair or deceptive is ultimately a question of law for the Court.

Songwooyarn Trading Co. v. Sox Eleven, Inc., 213 N.C. App. 49, 56 (2011).

115. As a preliminary matter, the Court has dismissed Plaintiffs’ claims for

fraud and fraudulent inducement, so those claims do not support a claim for unfair

and deceptive trade practices. A claim for violation of the UDTPA does not require

a separate, actionable, underlying claim for fraud. See Gress v. Rowboat Co., 190 N.C.

App. 773 (2008). However, the dismissal of the fraud claims supports the conclusion

that Plaintiffs have not produced evidence of deceptive conduct.

116. Further, although a breach of contract accompanied by “substantial

aggravating circumstances” can sustain a claim for violation of the UDTPA, Branch

Banking & Trust Co. v. Thompson, 107 N.C. App. 53, 62 (1992), the Court has

dismissed Plaintiffs’ claim for breach of the APA.

117. Therefore, to the extent PRA’s Motion seeks summary judgment on

Plaintiffs’ claim for violation of the UDTPA, PRA’s Motion should be GRANTED.

C. Plaintiffs’ Motion

118. Plaintiffs move for summary judgment on only two claims: (a) PRA’s

remaining counterclaim against Parthasarathy for breach of the Employment

Agreement and the Settlement Agreement, and (b) whether the license granted in

the Takeda MSA constitutes an “External Sale” under the MSA, potentially entitling

Plaintiffs to certain Sales Milestone payments. (ECF Nos. 116/117.1, at pp. 1–2.) The

Court will address these claims in turn.

1. PRA’s Counterclaim for Breach of Contract Against Parthasarathy

119. Plaintiffs seek summary judgment in their favor on PRA’s counterclaim

for breach of contract against Parthasarathy. The counterclaim alleges: (1) that

Parthasarathy did not use his “best efforts” on behalf of PRA, as required by the

Employment Agreement, because he devoted significant time and effort to forming

MGS; and (2) that “Parthasarathy’s breach of the Employment Agreement also

effectuated a breach of the Settlement Agreement, in which he represented that he

had ‘not breached any provision of the Employment Agreement.’” (ECF No. 37, at ¶¶

84–91.) In the counterclaim, PRA alleges “[a]s a direct and proximate result of

Parthasarathy’s breaches of the Parthasarathy Employment Agreement and

Settlement Agreement, PRA is entitled to actual damages, including the amount PRA

paid to Parthasarathy under the Settlement Agreement, plus attorneys’ fees and

interest.” (Id. at ¶ 91.)

120. In North Carolina, a party asserting breach of contract must show “(1)

existence of a valid contract; and (2) breach of the terms of that contract.” Cater v.

Barker, 172 N.C. App. 441, 445 (2005) (citing Poor v. Hill, 138 N.C. App. 19, 26

(2000)). In construing a contract, the courts are to give full effect to each

unambiguous contractual provision. Singleton v. Haywood Elec. Membership. Corp.,

357 N.C. 623, 629 (2003) (holding that “various terms of the [contract] are to be

harmoniously construed, and if possible, every word and every provision is to be given

effect”).

121. Our Court of Appeals has held, “[i]n order for a breach of contract to be

actionable it must be a material breach, one that substantially defeats the purpose of

the agreement or goes to the very heart of the agreement, or can be characterized as

a substantial failure to perform.” Supplee v. Miller-Motte Bus. Coll., Inc., 239 N.C.

App. 208, 220 (2015) (quoting Long v. Long, 160 N.C. App. 664, 668 (2003)). The

question of "[w]hether a breach is material or immaterial is ordinarily a question of

fact[.]" McClure Lumber Co. v. Helmsman Constr., Inc., 160 N.C. App. 190, 198

(2003).

122. It is undisputed that the Employment Agreement and Settlement

Agreement are valid contracts. It also is undisputed that Parthasarathy helped

found, served on the board of directors of, and did extensive work in furtherance of

MGS while still employed by PRA, and that Parthasarathy neither disclosed his

involvement with MGS to Shannon or PRA, nor sought PRA’s consent to engage in

his activities with MGS. Parthasarathy’s activities for MGS are at least arguably

breaches of the unambiguous obligations contained in sections 3(a)(i) and 3(a)(ii) of

the Employment Agreement.

123. Plaintiffs argue that the only breach of the Employment Agreement and

Separation Agreement that PRA is now pursuing is Parthasarathy’s failure to get

Shannon’s consent to serve on the MGS’s board of directors. (ECF Nos. 116/117.1, at

pp. 10–11.) Plaintiffs contend that PRA’s Rule 30(b)(6) corporate witnesses on the

breach of contract counterclaim, Irene, testified that the

sole basis for PRA’s “best efforts” counterclaim against Mr.

Parthasarathy is his failure “to inform PRA if he were on

the board of another company” and that PRA “not aware of

performance reasons for the counterclaim” and does not

claim that Mr. Parthasarathy’s claimed failure to give

notice had any impact on his performance of his job.

(Id. at p. 10.) Irene further testified that “PRA seeks the ‘$135,000 that was deposited

into [Parthasarathy’s] account as part of his severance agreement’” and “‘[s]o the

counterclaim is for the money paid to [Parthasarathy]. That is what the counterclaim

is. It’s not an evaluation of his job performance.’” (Id.)

124. Plaintiffs argue that Parthasarathy’s failure to notify PRA of his work

on MGS does not constitute a material breach such that rescissory damages should

be awarded to PRA. (Id. at pp. 10–11.) Plaintiffs further contend that “because PRA

does not seek any actual damages from the claimed breach, its counterclaim fails and

must be dismissed.” (Id. at p. 11; ECF Nos. 128/138, at p. 4.)

125. Finally, Plaintiffs argue that no North Carolina statute authorizes

PRA’s recovery of attorneys’ fees and that the “contractual provision PRA relies on is

an ‘indemnification’ clause in the Employment Separation Agreement.” (Id. at p. 12.)

126. In response, PRA argues that Plaintiffs’ contention that PRA admitted

that its counterclaim is based solely on Parthasarathy’s failure to notify PRA that he

was serving on MGS’s board of directors is a “gross” mischaracterization of Irene’s

testimony, and that Irene testified repeatedly that the counterclaim was based on

Parthasarathy’s work on behalf of MGS while still employed with PRA as well as his

failure to inform Shannon that he served on the board. (ECF Nos. 120/122, at p. 7.)

The Court has reviewed the relevant testimony and concludes that PRA is correct;

Irene testified on multiple occasions that PRA’s claim was based on Parthasarathy’s

employment with and work on behalf of MSG as well as his failure to notify Shannon.

PRA has not limited its breach of contract counterclaim to Parthasarathy’s failure to

inform Shannon that he was serving on MGS’s board of directors.

127. PRA next contends that it is not seeking the equitable remedy of

“recission” of the Settlement Agreement, but instead is seeking as actual damages

the amount it paid to Parthasarathy as separation pay. (Id. at pp. 8–9.) PRA claims

it merely seeks “compensation” for Parthasarathy’s breach of the Settlement

Agreement that would place it “in the same position he would have occupied if the

contract had been performed.” (Id. at p. 9.)

128. PRA further argues that it is not required to prove it suffered actual

damages to survive summary judgment on a claim for breach of contract. (Id. at p.

6.) PRA is correct. See Midgett v. N.C. State Highway Comm'n, 265 N.C. 373 (N.C.

1965) (“When plaintiff proves breach of contract he is entitled at least to nominal

damages.”) (quotation and citation omitted); Crescent Univ. City Venture, LLC v. AP

Atl., Inc., 2019 NCBC LEXIS 46, at *127 (N.C. Bus. Ct. Aug. 8, 2019) (“[I]in a suit for

damages for breach of contract, proof of the breach would entitle the plaintiff to

nominal damages at least.”) (citing Delta Envtl. Consultants, Inc. v. Wysong & Miles

Co., 132 N.C. App. 160, 172 (1999))); Comm. to Elect Forest v. Emples. Political Action

Comm., 260 N.C. App. 1, 6–7 (2018) (“[O]ne has standing to seek nominal damages

where some legal right has been invaded but no actual loss or substantial injury has

been sustained. Nominal damages are awarded in recognition of the right and of the

technical injury resulting from its violation.”) (internal quotation omitted).

129. The Court has considered Plaintiffs’ arguments in support of entering

summary judgment against PRA on its claim for breach of the Employment

Agreement and Settlement Agreement and concludes that Plaintiff’s Motion on these

claims must fail. There is no dispute that the Employment Agreement and

Settlement Agreement are enforceable contracts, and there is evidence upon which a

finder of fact could find Parthasarathy’s activities for MGS were a material breach of

at least sections 3(a)(i) and 3(a)(ii) of the Employment Agreement and of

representations in the Settlement Agreement. PRA may be entitled to at least

nominal damages for such breaches. Therefore, to the extent that Plaintiffs seek

summary judgment in their favor as to PRA’s counterclaim for breach of the

Employment Agreement and Settlement Agreement, Plaintiffs’ Motion should be

DENIED.

130. Regarding PRA’s counterclaim for breach of the Settlement Agreement,

Plaintiffs also argue that PRA cannot recover attorneys’ fees from Plaintiffs as a

matter of law. Plaintiffs contend that the provision in the Settlement Agreement

requiring Parthasarathy to indemnify PRA for its attorneys’ fees and costs for

pursuing its claim for breach of the Employment Agreement is unenforceable because

there is no statute authorizing an award of attorneys’ fees. (ECF Nos. 116/117.1, at

pp. 11–12.) North Carolina adheres to the “American Rule” that a “successful litigant

may not recover attorneys' fees, whether as costs or as an item of damages, unless

such a recovery is expressly authorized by statute.” Stillwell Enter. v. Interstate

Equip. Co., 300 N.C. 286, 289 (1980) (citing Hicks v. Albertson, 284 N.C. 236 (1972));

see also Burr v. Burr, 153 N.C. App. 504, 506 (2002) (“The recovery of attorney’s fees

is a right created by statute.”); Wiggins v. Bright, 198 N.C. App. 692, 695 (2009) (“A

trial court cannot award attorneys’ fees unless specifically authorized by statute.”).

This is true “[e]ven in the face of a carefully drafted contractual provision

indemnifying a party for such attorneys’ fees as may be necessitated by a successful

action on the contract itself.” Stillwell Enter., 300 N.C. at 289 (citing Howell v.

Roberson, 197 N.C. 572 (1929) and Tinsley v. Hoskins, 111 N.C. 340 (1892)). 9

131. PRA does not contend that there is statutory authority for its claim for

attorneys’ fees in this case. Instead, it argues that “[w]here, as here, parties agree to

an attorney’s fees provision in a settlement agreement, such a provision is enforceable

under North Carolina law,” citing in support Ehrenhaus v. Baker, 243 N.C. App. at

28, and other cases.

132. PRA misinterprets Ehrenhaus and its application to the facts in this

lawsuit. In Ehrenhaus, the court held that the defendants’ agreement to pay the

plaintiffs’ attorneys fees in consideration for, and as part of, a settlement agreement

resolving pending claims between the parties was permissible even absent statutory

authority since North Carolina “recognizes the enforceability of settlement

agreements providing for the payment of one party’s attorneys’ fees by the other party

to the lawsuit.” Id. at 28 (citing Carter v. Foster, 103 N.C. App. 110, 114–15 (1991)).

The Court recognized “that giving effect to a negotiated settlement agreement

providing for the payment of one party’s attorneys’ fees by the other party is

consistent with the well-established policy of encouraging the settlement of disputes

between litigants” and does not implicate the public policy concerns addressed by the

American Rule. Id. at 27–28 (stating that the “rationale underlying American Rule

9 By statute, North Carolina has created a narrow exception to this rule in circumstances

where there are “[r]eciprocal attorneys’ fees provisions [contained] in business contracts.”

N.C.G.S. § 6-21.6. It is undisputed that the attorneys’ fees provision at issue in this case is

not reciprocal but, instead, inures only to the benefit of PRA.

is that attorney fee awards against the non-prevailing party have a chilling effect on

open access to the courts.”) (quotation and citation omitted).

133. Unlike in Ehrenhaus, the attorneys’ fees provision here, although

contained within a document title “Confidential Release and Settlement Agreement,”

does not require Plaintiffs to pay attorneys’ fees in settlement of an existing dispute

between the parties. Rather, it is simply a device for requiring Plaintiffs to pay PRA’s

attorneys’ fees in the event PRA pursues a “claim” and proves that Parthasarathy

made a misrepresentation regarding his compliance with the terms of the

Employment Agreement. In other words, it provides for the payment of PRA’s

attorneys’ fees if PRA is the prevailing party on such a claim. This is easily

distinguishable from the type of attorneys’ fees agreement enforced in Ehrenhaus.

134. The Court has carefully considered the arguments and concludes that

the terms of the Settlement Agreement requiring Plaintiffs to pay PRA’s attorneys’

fees is unenforceable as a matter of law. GR&S Atl. Beach, LLC v. Hull, 2011 NCBC

LEXIS 38, at *2 (N.C. Super. Ct. Sept. 29, 2011) (stating that attorneys’ fees

“incurred in litigation between parties are not recoverable by the successful party in

the absence of statutory authorization, whether they are claimed as costs or damages

and whether or not an agreement between the parties expressly allows for the

recovery of such fees”). Accordingly, to the extent Plaintiffs’ Motion seeks summary

judgment in Plaintiffs’ favor dismissing PRA’s counterclaim for attorneys’ fees and

costs, Plaintiffs’ Motion should be GRANTED.

2. Plaintiffs’ claim that the license granted in the Takeda MSA constitutes an

“External Sale” under the APA

135. In the Amended Complaint, Plaintiffs allege that “PRA entered into

transactions with Takeda (and, on information and belief, other customers) that

qualify as External Sales under the APA but has failed to pay the variable milestone

payments associated with the sales milestone.” (ECF No. 60.1, at ¶131.) Plaintiffs

now seek summary judgment on the issue of whether the license to access PSO

provided by PRA to Takeda constitutes an External Sale under the APA. 10

136. The relevant terms of the Takeda MSA are not in dispute. In or around

July 2016 PRA entered into the Takeda MSA. Under the Takeda MSA, PRA was to

provide services to Takeda including assistance with clinical trial management in

exchange for compensation by Takeda. The Takeda MSA grants Takeda the right to

access and use the “PRAHS Owned Technology” that PRA used in supporting or

providing the services. Under the Takeda MSA, “PRAHS Owned Technology”

includes the Solutions. The Takeda MSA does not expressly provide that a defined

amount or percentage of the compensation paid by Takeda for PRA’s services is

attributable to the license to access and use the Solutions.

137. To determine whether the Takeda MSA is an External Sale, the Court

must interpret the meaning of that term as used in the APA. Summarizing

Delaware’s rules of contract construction, the Delaware Supreme Court held:

10 In its Order on Rule 10.9 Discovery Dispute (ECF No. 82), the Court ordered that “[t]he

parties shall include as part of their briefing on motions for summary judgment, . . . argument

regarding whether the type of access to PSO granted by the Takeda Agreement is an

“External Sale” under the APA.” (Id. at p. 7.)

Clear and unambiguous language . . . should be given its

ordinary and usual meaning. Absent some ambiguity,

Delaware courts will not destroy or twist [contract]

language under the guise of construing it. When the

language of a . . . contract is clear and unequivocal, a party

will be bound by its plain meaning because creating an

ambiguity where none exists could, in effect, create a new

contract with rights, liabilities and duties to which the

parties had not assented. . . .

A contract is not rendered ambiguous simply because the

parties do not agree upon its proper construction. Rather,

a contract is ambiguous only when the provisions in

controversy are reasonably or fairly susceptible of different

interpretations or may have two or more different

meanings. Ambiguity does not exist where a court can

determine the meaning of a contract without any other

guide than a knowledge of the simple facts on which, from

the nature of language in general, its meaning depends.

Courts will not torture contractual terms to impart

ambiguity where ordinary meaning leaves no room for

uncertainty. The true test is not what the parties to the

contract intended it to mean, but what a reasonable person

in the position of the parties would have thought it meant.

Lorillard Tobacco Co. v. Am. Legacy Found., 903 A.2d 728, 739 (2006) (quoting

Rhone-Poulenc, 616 A.2d at 1195–96). “The determination of ambiguity lies within

the sole province of the court.” Estate of Osborn, 991 A.2d 1160.

138. “[W]here the language at issue is clear and unambiguous. . . . the parol

evidence rule bars the admission of evidence from outside the contract's four corners

to vary or contradict that unambiguous language.” GMG Capital Invs., LLC, 36 A.3d

at 783. “But, where reasonable minds could differ as to the contract's meaning, a

factual dispute results and the fact-finder must consider admissible extrinsic

evidence. In those cases, summary judgment is improper.” Id.

139. A contract term or phrase is not ambiguous merely because the parties

dispute its proper construction. Lorillard Tobacco Co., 903 A.2d at 73. Rather,

[i]f parties introduce conflicting interpretations of a term,

but one interpretation better comports with the remaining

contents of the document or gives effect to all the words in

dispute, the court may, as a matter of law and without

resorting to extrinsic evidence, resolve the meaning of the

disputed term in favor of the superior interpretation.

Wills v. Morris, James, Hitchens, & Williams, 1998 Del. Ch. LEXIS 213, *4-5 (Nov. 6,

1998) (citing E.I. duPont de Nemours v. Shell Oil Co., 498 A.2d 1108, 1113 (Del.

1985)).

140. With these rules of construction in mind, the Court turns to the relevant

language and provisions of the APA.

141. The APA states, in pertinent part, that External Sale “means the sale of

one or more licenses to the Solutions by [PRA] . . . to a third party.” (ECF No. 112, at

p. 352.) Clin Trial Max, Cloud Max, and Info Max are defined as the Solutions. (Id.

at p. 349.) The APA provides that Plaintiffs will earn incentive payments for the

achievement of the Sales Milestones upon “the achievement of aggregate External

Sales” within certain proscribed time periods following the Closing Date. (Id. at p.

374.) The Sales Milestones are separate from, and in addition to, the Development

Milestones tied to the functionality of the Solutions and their deployment within PRA

clinical trial management environment. (Id. at pp. 351–52.)

142. Plaintiffs do not argue that the meaning of the term External Sale is

unambiguous. (ECF Nos. 116/117.1, at pp. 4, 13–16; ECF Nos. 128/138, at pp. 8–16.)

Instead, relying heavily on deposition testimony and other extrinsic evidence,

Plaintiffs contend that the definition of External Sale in the APA is broad enough to

“to capture the ‘myriad’ types of licensing transactions that would permit PRA to

commercially exploit the value of the Solutions.” (ECF Nos. 116/117.1, at pp. 4, 13–

16; ECF Nos. 128/138, at pp. 8–16.) Plaintiffs argue that nothing contained in the

definition of External Sale requires that “the transaction between PRA and PRA’s

customer” has to “be a software sales transaction or memorialized as a licensing

agreement.” (ECF Nos. 116/117.1, at p. 14.) Plaintiffs argue that “the Takeda MSA

includes an express license to Takeda of the Solutions used by PRA to provide

services,” that PRA has in fact used the Solutions to provide services to Takeda, and

that the transaction qualifies as an External Sale. (Id.)

143. PRA argues that the term External Sale in the APA is unambiguous,

and therefore the Court should not consider the extrinsic evidence offered by

Plaintiffs. (ECF Nos. 120/122, at pp. 17–24.) PRA contends that the word “sale is

generally understood to involve a conveyance of something in exchange for a payment

for that which is being conveyed” and cites a dictionary definition of “sale” as “the

transfer of ownership of and title to something “for a price.” (ECF No. 120/122, at p.

14.) PRA argues that providing its customers access to PRA’s technology and

software, including the Solutions, as part of providing clinical trial management

services to the customer without charging a fee for the access is not an External Sale.

PRA further asserts that Plaintiffs’ proposed interpretation would lead to “absurd

results” because “[u]nder Plaintiffs’ interpretation, PRA would apparently make a

‘sale’ of [the Solutions] any time it entered into a contract that either i) allowed the

customer the general right to access and use PRA’s technology; or ii) disclosed on an

exhibit which technology applications PRA might use internally in providing clinical

trial services to a customer.” (Id. at p. 23.)

144. PRA also notes that the Takeda MSA does not expressly use the word

sale in connection with the license, and that there is no separate fee attributed to the

access to the Solutions. (Id.) PRA also argues that the “overall structure” of the

transaction, which involved a large number of Takeda employees transferring to work

on-site at PRA, suggests the license was simply a means for making it easier to work

“collaboratively.” (Id. at pp. 15–16.) PRA contends that merely providing a customer

access to and use of PSO as part of providing services is not a sale.

145. The Court begins by assessing the language used by the parties to define

the term External Sale in the APA. The key language at issue is “the sale of one or

more licenses to the Solutions by [PRA] . . . to a third party.” (ECF No. 112.1, at p.

374.) “License” is a familiar term when used in connection with software, typically

meaning a limited right to access and use a software product owned by another entity.

This meaning generally comports with an accepted dictionary definition of “license”

as “a grant by the holder of a copyright or patent to another of any of the rights

embodied in the copyright or patent short of an assignment of all rights.” License,

MERRIAM-WEBSTER.COM, https://www.merriam-webster.com/dictionary/license (last

visited Mar. 30, 2021). As PRA contends, “[a] ‘sale’ is generally understood to involve

a conveyance of something in exchange for a payment for that which is being

conveyed.” (ECF Nos. 120/122, at p. 14.) A common sense reading of the definition

of External Sale strongly suggests that an External Sale contemplates the payment

of a specific fee by a customer for the right use of the Solution.

146. This construction of the definition of External Sale is also consistent

with the overall purposes and structure of the APA. See E.I. duPont de Nemours v.

Shell Oil Co., 498 A.2d at 1113 (“In upholding the intentions of the parties, a court

must construe the agreement as a whole, giving effect to all provisions therein.

Moreover, the meaning which arises from a particular portion of an agreement cannot

control the meaning of the entire agreement where such inference runs counter to the

agreement's overall scheme or plan.”). In the APA, PRA purchased all of Plaintiffs’

proprietary rights and interests in the Solutions and became the owner of the

Solutions. Part of the compensation for the purchase was structured as incentive

payments to Plaintiffs for successfully and timely integrating the Solutions into

PRA’s clinical trial management environment in order for PRA to better provide

services to its customers―services for which it had an established revenue stream.

(ECF No. 112.1, at pp. 351–52.) A second and distinct set of incentive payments were

tied to PRA’s ability to create a new revenue stream derived from selling licenses to

the Solutions to customers. (Id. at p. 352.) The incentives are expressly tied to the

income generated by PRA from selling the licenses, and not an increase in PRA’s

overall revenue from providing its clinical trial management services caused by PRA’s

internal use of the Solution. 11

147. Plaintiffs and PRA offer differing interpretations of the term External

Sales. However, “[i]f parties introduce conflicting interpretations of a term, but one

11 The Court believes that a sale of a license to the Solutions could occur within an overall

services agreement between PRA and its customers if a separate and specific fee were

attributed to the license or licenses.

interpretation better comports with the remaining contents of the document or gives

effect to all the words in dispute, the court may, as a matter of law and without

resorting to extrinsic evidence, resolve the meaning of the disputed term in favor of

the superior interpretation.” Wills, 1998 Del. Ch. LEXIS 213, at *4-5. PRA urges the

language “the sale of one or more licenses to the Solutions by [PRA] . . . to a third

party” means the sale of a right to access and use the Solution for a specific payment

In this case, PRA has offered the “superior interpretation” of the meaning of External

Sale as being the grant of a license by PRA to a third party to use the Solutions in

exchange for a specific fee or payment attributable solely or separately to the license.

The Court concludes that the term External Sale is unambiguous and is not “fairly

susceptible of different interpretations,” and “a reasonable person in the position of

the parties would have thought [External Sales] meant” the grant of license by PRA

to a third party to use the Solutions in exchange for a specific fee or payment

attributable solely or separately to the license. Lorillard Tobacco Co.., 903 A.2d at

739.

148. Accordingly, to the extent Plaintiffs seek summary judgment in their

favor in finding that the Takeda MSA constituted an External Sale within the

meaning of the APA, Plaintiffs’ Motion should be DENIED. To the extent PRA’s

Motion seeks summary judgment on Plaintiffs’ claim that the Takeda MSA

constituted an External Sale within the meaning of the APA, PRA’s Motion should be

GRANTED.

IV. CONCLUSION 12

THEREFORE, IT IS ORDERED, as follows:

1. PRA’s Motion is GRANTED.

2. To the extent Plaintiffs’ Motion seeks summary judgment in Plaintiffs’

favor as to PRA’s counterclaim for breach of the Employment Agreement

and Settlement Agreement, Plaintiffs’ Motion is DENIED.

3. To the extent Plaintiffs’ Motion seeks the entry of summary judgment in

Plaintiffs’ favor dismissing PRA’s counterclaim for attorneys’ fees and costs,

Plaintiffs’ Motion is GRANTED.

4. To the extent Plaintiffs’ Motion seeks the entry of summary judgment in

Plaintiffs’ favor finding the Takeda MSA constituted an External Sale

within the meaning of the APA, Plaintiffs’ Motion is DENIED.

5. To the extent PRA’s Motion seeks summary judgment on Plaintiffs’ claim

that the Takeda MSA constituted an External Sale within the meaning of

the APA, PRA’s Motion is GRANTED.

12 PRA also seeks summary judgment on its argument that the APA requires that claims

arising under the APA be tried to the Court without a jury and not to a jury, and that

Plaintiffs waived their right to a jury trial. (ECF No. 110, at p. 5.) Since the Court has

dismissed Plaintiffs’ remaining claims, the argument is moot. Therefore, to the extent PRA’s

Motion seeks summary judgment on this argument, PRA’s Motion is DENIED without

prejudice.

SO ORDERED, this the 5th day of April, 2021.

/s/ Gregory P. McGuire

Gregory P. McGuire

Special Superior Court Judge for

Complex Business Cases